<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Juvenile Idiopathic Arthritis | Australian Living Guidelines</title>
    
    <meta name="description" content="Evidence-based clinical recommendations for the management of juvenile idiopathic arthritis (JIA). Developed by ANZMUSC, Australian Rheumatology Association, and Cochrane Musculoskeletal.">
    <meta name="keywords" content="juvenile idiopathic arthritis, JIA guidelines, paediatric rheumatology, methotrexate JIA, biologic therapy children, DMARDs children, Australian guidelines">
    <meta name="author" content="ANZMUSC Clinical Trials Network">
    <meta name="robots" content="index, follow">
    <link rel="canonical" href="https://livingguidelines.org/jia/">
    
    <meta property="og:type" content="website">
    <meta property="og:url" content="https://livingguidelines.org/jia/">
    <meta property="og:title" content="Juvenile Idiopathic Arthritis | Australian Living Guidelines">
    <meta property="og:description" content="Evidence-based clinical recommendations for the management of juvenile idiopathic arthritis (JIA).">
    <meta property="og:site_name" content="Australian Living Guidelines">
    
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "MedicalGuideline",
        "name": "Australian Living Guideline for Juvenile Idiopathic Arthritis",
        "description": "Evidence-based clinical recommendations for the management of juvenile idiopathic arthritis (JIA).",
        "url": "https://livingguidelines.org/jia/",
        "publisher": {"@type": "Organization", "name": "ANZMUSC Clinical Trials Network"},
        "about": {"@type": "MedicalCondition", "name": "Juvenile Idiopathic Arthritis"}
    }
    </script>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Source+Sans+3:wght@300;400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    <style>
        :root {
            --primary-blue: #1e3a5f;
            --primary-teal: #0d9488;
            --jia-purple: #7c3aed;
            --jia-purple-light: #8b5cf6;
            --jia-purple-dark: #6d28d9;
            --accent-orange: #f97316;
            --text-dark: #1f2937;
            --text-medium: #4b5563;
            --text-light: #6b7280;
            --bg-cream: #fefdfb;
            --bg-light: #f8fafc;
            --bg-blue-light: #f0f9ff;
            --border-light: #e5e7eb;
            --border-medium: #d1d5db;
            --white: #ffffff;
            --shadow-md: 0 4px 6px -1px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 15px -3px rgba(0,0,0,0.1);
            --radius-sm: 6px;
            --radius-md: 10px;
            --radius-lg: 16px;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { font-family: 'Source Sans 3', -apple-system, BlinkMacSystemFont, sans-serif; color: var(--text-dark); line-height: 1.6; background-color: var(--bg-cream); }
        
        header { background: var(--white); border-bottom: 1px solid var(--border-light); position: sticky; top: 0; z-index: 1000; }
        .header-top { background: var(--primary-blue); padding: 8px 0; }
        .header-top-content { max-width: 1200px; margin: 0 auto; padding: 0 24px; display: flex; justify-content: flex-end; gap: 24px; }
        .header-top a { color: rgba(255,255,255,0.85); text-decoration: none; font-size: 13px; font-weight: 500; }
        .header-top a:hover { color: var(--white); }
        .header-main { max-width: 1200px; margin: 0 auto; padding: 16px 24px; display: flex; justify-content: space-between; align-items: center; flex-wrap: wrap; gap: 16px; }
        .logo { display: flex; align-items: center; gap: 16px; text-decoration: none; }
        .logo-image { height: 50px; width: auto; }
        .logo-text { display: flex; flex-direction: column; }
        .logo-title { font-family: 'Source Serif 4', Georgia, serif; font-size: 22px; font-weight: 600; color: var(--primary-blue); }
        .logo-subtitle { font-size: 13px; color: var(--text-light); }
        nav { display: flex; gap: 8px; flex-wrap: wrap; }
        .nav-item { position: relative; }
        .nav-link { display: flex; align-items: center; gap: 6px; padding: 10px 16px; color: var(--text-medium); text-decoration: none; font-size: 15px; font-weight: 500; border-radius: var(--radius-sm); transition: all 0.2s; }
        .nav-link:hover { color: var(--jia-purple); background: var(--bg-light); }
        .nav-link svg { width: 14px; height: 14px; transition: transform 0.2s; }
        .nav-item:hover .nav-link svg { transform: rotate(180deg); }
        .dropdown { position: absolute; top: 100%; left: 0; min-width: 220px; background: var(--white); border-radius: var(--radius-md); box-shadow: var(--shadow-lg); border: 1px solid var(--border-light); opacity: 0; visibility: hidden; transform: translateY(10px); transition: all 0.2s; padding: 8px; z-index: 100; }
        .nav-item:hover .dropdown { opacity: 1; visibility: visible; transform: translateY(0); }
        .dropdown a { display: block; padding: 10px 14px; color: var(--text-medium); text-decoration: none; font-size: 14px; border-radius: var(--radius-sm); }
        .dropdown a:hover { background: var(--bg-light); color: var(--jia-purple); }
        
        .hero { background: linear-gradient(135deg, #1e3a5f 0%, #3d3266 100%); padding: 80px 24px; }
        .hero-content { max-width: 1200px; margin: 0 auto; }
        .hero h1 { font-family: 'Source Serif 4', Georgia, serif; font-size: clamp(28px, 5vw, 44px); font-weight: 600; color: var(--white); margin-bottom: 20px; max-width: 700px; line-height: 1.2; }
        .hero-description { font-size: 19px; color: rgba(255,255,255,0.9); max-width: 600px; line-height: 1.7; margin-bottom: 32px; }
        .hero-badges { display: flex; flex-wrap: wrap; gap: 12px; margin-bottom: 32px; }
        .hero-badge { display: inline-flex; align-items: center; gap: 8px; padding: 8px 16px; background: rgba(255,255,255,0.15); border-radius: 100px; color: var(--white); font-size: 14px; font-weight: 500; }
        .hero-badge svg { width: 16px; height: 16px; }
        .hero-cta { display: inline-flex; align-items: center; gap: 10px; padding: 14px 28px; background: var(--white); color: var(--jia-purple); text-decoration: none; font-size: 16px; font-weight: 600; border-radius: var(--radius-md); transition: all 0.2s; box-shadow: 0 4px 14px rgba(0,0,0,0.15); }
        .hero-cta:hover { background: var(--bg-light); transform: translateY(-2px); }
        .hero-cta svg { width: 18px; height: 18px; }
        
        .main-content { padding: 40px 24px 60px; }
        .content-container { max-width: 1200px; margin: 0 auto; }
        
        .filter-section { margin-bottom: 32px; }
        .search-container { max-width: 500px; margin: 0 auto 24px; position: relative; }
        .search-input { width: 100%; padding: 14px 20px 14px 48px; font-size: 16px; border: 2px solid var(--border-light); border-radius: var(--radius-md); background: var(--white); color: var(--text-dark); transition: all 0.2s; }
        .search-input:focus { outline: none; border-color: var(--jia-purple); box-shadow: 0 0 0 3px rgba(124,58,237,0.1); }
        .search-input::placeholder { color: var(--text-light); }
        .search-icon { position: absolute; left: 16px; top: 50%; transform: translateY(-50%); width: 20px; height: 20px; color: var(--text-light); pointer-events: none; }
        .search-clear { position: absolute; right: 12px; top: 50%; transform: translateY(-50%); width: 24px; height: 24px; border: none; background: var(--bg-light); border-radius: 50%; cursor: pointer; display: none; align-items: center; justify-content: center; color: var(--text-medium); }
        .search-clear:hover { background: var(--border-light); }
        .search-clear.visible { display: flex; }
        
        .filter-label { font-size: 13px; font-weight: 600; color: var(--text-light); text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 12px; text-align: center; }
        .tag-filters { display: flex; justify-content: center; gap: 8px; flex-wrap: wrap; max-width: 900px; margin: 0 auto; }
        .tag-filter { padding: 6px 14px; background: var(--white); border: 1px solid var(--border-light); border-radius: 100px; font-size: 13px; font-weight: 500; color: var(--text-medium); cursor: pointer; transition: all 0.2s; }
        .tag-filter:hover { border-color: var(--jia-purple); color: var(--jia-purple); }
        .tag-filter.active { background: var(--jia-purple); color: var(--white); border-color: var(--jia-purple); }
        
        .no-results { text-align: center; padding: 60px 20px; color: var(--text-light); display: none; }
        .no-results h3 { font-size: 18px; color: var(--text-medium); margin-bottom: 8px; }
        
        .recommendations-grid { display: grid; grid-template-columns: repeat(auto-fill, minmax(340px, 1fr)); gap: 24px; }
        .recommendation-card { background: var(--white); border: 1px solid var(--border-light); border-radius: var(--radius-lg); overflow: hidden; transition: all 0.3s; cursor: pointer; display: flex; flex-direction: column; }
        .recommendation-card:hover { border-color: var(--jia-purple); box-shadow: var(--shadow-lg); transform: translateY(-4px); }
        .recommendation-card.hidden { display: none; }
        .card-header { padding: 20px 24px; border-bottom: 1px solid var(--border-light); display: flex; justify-content: space-between; align-items: flex-start; gap: 16px; }
        .card-category { font-size: 12px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; color: var(--jia-purple); margin-bottom: 8px; }
        .card-title { font-family: 'Source Serif 4', Georgia, serif; font-size: 18px; font-weight: 600; color: var(--text-dark); line-height: 1.4; }
        .card-strength { display: flex; flex-direction: column; align-items: center; gap: 4px; flex-shrink: 0; }
        .strength-indicator { width: 36px; height: 36px; border-radius: 50%; display: flex; align-items: center; justify-content: center; }
        .strength-indicator svg { width: 18px; height: 18px; color: var(--white); }
        .strength-indicator.strong-for { background: linear-gradient(135deg, #10b981 0%, #059669 100%); }
        .strength-indicator.conditional-for { background: linear-gradient(135deg, #eab308 0%, #ca8a04 100%); }
        .strength-indicator.conditional-against { background: linear-gradient(135deg, var(--accent-orange) 0%, #ea580c 100%); }
        .strength-indicator.strong-against { background: linear-gradient(135deg, #ef4444 0%, #dc2626 100%); }
        .strength-label { font-size: 10px; font-weight: 600; text-transform: uppercase; color: var(--text-light); text-align: center; line-height: 1.3; }
        .card-body { padding: 20px 24px; flex: 1; }
        .card-recommendation { font-size: 15px; color: var(--text-medium); line-height: 1.6; margin-bottom: 16px; display: -webkit-box; -webkit-box-orient: vertical; -webkit-line-clamp: 8; overflow: hidden; }
        .card-tags { display: flex; flex-wrap: wrap; gap: 6px; }
        .card-tag { padding: 4px 10px; background: var(--bg-light); border-radius: 100px; font-size: 12px; font-weight: 500; color: var(--text-light); }
        .card-footer { padding: 16px 24px; background: var(--bg-light); display: flex; justify-content: space-between; align-items: center; border-top: 1px solid var(--border-light); margin-top: auto; }
        .card-link { font-size: 13px; font-weight: 600; color: var(--jia-purple); display: flex; align-items: center; gap: 6px; }
        .card-link svg { width: 16px; height: 16px; }
        .card-updated { font-size: 12px; color: var(--text-light); }
        
        .modal-overlay { position: fixed; top: 0; left: 0; right: 0; bottom: 0; background: rgba(0,0,0,0.5); z-index: 2000; display: none; align-items: center; justify-content: center; padding: 24px; backdrop-filter: blur(4px); }
        .modal-overlay.active { display: flex; }
        .modal-content { background: var(--white); border-radius: var(--radius-lg); max-width: 900px; width: 100%; max-height: 90vh; overflow: hidden; display: flex; flex-direction: column; box-shadow: 0 25px 50px -12px rgba(0,0,0,0.25); }
        .modal-header { padding: 24px 32px; border-bottom: 1px solid var(--border-light); display: flex; justify-content: space-between; align-items: flex-start; gap: 20px; }
        .modal-category { font-size: 13px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; color: var(--jia-purple); margin-bottom: 8px; }
        .modal-title { font-family: 'Source Serif 4', Georgia, serif; font-size: 24px; font-weight: 600; color: var(--text-dark); line-height: 1.3; }
        .modal-close { width: 40px; height: 40px; border: none; background: var(--bg-light); border-radius: 50%; cursor: pointer; display: flex; align-items: center; justify-content: center; flex-shrink: 0; }
        .modal-close:hover { background: var(--border-light); }
        .modal-close svg { width: 20px; height: 20px; color: var(--text-medium); }
        .modal-tabs { display: flex; flex-wrap: nowrap; padding: 0 32px; border-bottom: 1px solid var(--border-light); background: var(--bg-light); overflow-x: auto; min-height: 50px; -webkit-overflow-scrolling: touch; scrollbar-width: none; -ms-overflow-style: none; }
        .modal-tabs::-webkit-scrollbar { display: none; }
        .modal-tabs-container { position: relative; }
        .modal-tabs-container::after { content: ''; position: absolute; top: 0; right: 0; bottom: 1px; width: 40px; background: linear-gradient(to right, transparent, var(--bg-light)); pointer-events: none; z-index: 1; }
        .modal-tab { padding: 16px 20px; font-size: 14px; font-weight: 600; color: var(--text-light); cursor: pointer; border: none; border-bottom: 3px solid transparent; margin-bottom: -1px; white-space: nowrap; background: none; }
        .modal-tab:hover { color: var(--text-medium); background: rgba(0,0,0,0.02); }
        .modal-tab.active { color: var(--jia-purple); border-bottom-color: var(--jia-purple); background: var(--white); }
        .modal-body { padding: 32px; overflow-y: auto; flex: 1; }
        .tab-content { display: none; }
        .tab-content.active { display: block; }
        
        .recommendation-box { background: var(--bg-blue-light); border-left: 5px solid var(--primary-teal); padding: 24px 28px; border-radius: 0 var(--radius-md) var(--radius-md) 0; margin-bottom: 24px; }
        .recommendation-box p { font-family: 'Source Serif 4', Georgia, serif; font-size: 18px; font-weight: 600; color: var(--primary-blue); line-height: 1.7; margin-bottom: 16px; }
        .recommendation-box p:last-child { margin-bottom: 0; }
        
        .remark-box { background: var(--bg-light); padding: 16px 20px; border-radius: var(--radius-md); margin-bottom: 24px; border: 1px solid var(--border-light); }
        .remark-box p { font-size: 15px; color: var(--text-medium); line-height: 1.7; font-style: italic; margin-bottom: 12px; }
        .remark-box p:last-child { margin-bottom: 0; }
        
        .strength-badge { display: inline-flex; align-items: center; gap: 8px; padding: 8px 14px; border-radius: 100px; font-size: 13px; font-weight: 600; margin-bottom: 20px; }
        .strength-badge.conditional-for { background: rgba(234,179,8,0.15); color: #a16207; }
        .strength-badge.conditional-against { background: rgba(249,115,22,0.15); color: #c2410c; }
        .strength-badge.strong-for { background: rgba(16,185,129,0.15); color: #047857; }
        .strength-badge.strong-against { background: rgba(239,68,68,0.15); color: #b91c1c; }
        
        .content-section { margin-bottom: 28px; }
        .content-section:last-child { margin-bottom: 0; }
        .content-section h3 { font-size: 18px; font-weight: 600; color: var(--text-dark); margin-bottom: 16px; }
        .content-section p { font-size: 15px; color: var(--text-medium); line-height: 1.8; margin-bottom: 16px; }
        .content-section p:last-child { margin-bottom: 0; }
        .content-section ul { padding-left: 24px; margin: 16px 0; }
        .content-section li { font-size: 15px; color: var(--text-medium); line-height: 1.7; margin-bottom: 10px; padding-left: 4px; }
        .content-section li:last-child { margin-bottom: 0; }
        
        .etd-domain { margin-bottom: 24px; padding: 20px; background: var(--bg-light); border-radius: var(--radius-md); border: 1px solid var(--border-light); }
        .etd-domain:last-child { margin-bottom: 0; }
        .etd-domain-header { display: flex; justify-content: space-between; align-items: center; margin-bottom: 12px; flex-wrap: wrap; gap: 8px; }
        .etd-domain-title { font-size: 16px; font-weight: 600; color: var(--text-dark); }
        .etd-rating { display: inline-block; padding: 4px 12px; background: var(--white); border: 1px solid var(--border-medium); border-radius: 100px; font-size: 12px; font-weight: 600; color: var(--text-medium); }
        .etd-domain-text { font-size: 14px; color: var(--text-medium); line-height: 1.8; }
        .etd-domain-text p { margin-bottom: 12px; }
        .etd-domain-text p:last-child { margin-bottom: 0; }
        .etd-domain-text ul { padding-left: 20px; margin: 12px 0; }
        .etd-domain-text li { margin-bottom: 8px; line-height: 1.7; }
        
        .pico-section { margin-bottom: 24px; }
        .pico-box { margin-bottom: 24px; }
        .pico-box h3 { font-size: 16px; font-weight: 600; color: var(--text-dark); margin-bottom: 12px; display: flex; align-items: center; }
        .pico-box h3 svg { width: 18px; height: 18px; margin-right: 8px; color: var(--jia-purple); }
        .pico-box .pico-text { font-size: 15px; color: var(--text-medium); line-height: 1.7; background: var(--bg-light); padding: 16px; border-radius: var(--radius-md); border-left: 3px solid var(--jia-purple); }

        .pico-section h3 { font-size: 16px; font-weight: 600; color: var(--text-dark); margin-bottom: 12px; }
        .pico-text { font-size: 15px; color: var(--text-medium); line-height: 1.7; }
        .evidence-section h3 { font-size: 16px; font-weight: 600; color: var(--text-dark); margin-bottom: 12px; }
        .evidence-note { font-size: 14px; color: var(--text-medium); }
        
        .modal-footer { padding: 20px 32px; border-top: 1px solid var(--border-light); display: flex; justify-content: space-between; align-items: center; background: var(--bg-light); flex-wrap: wrap; gap: 16px; }
        .magicapp-link { display: inline-flex; align-items: center; gap: 8px; padding: 12px 20px; background: var(--primary-blue); color: var(--white); text-decoration: none; font-size: 14px; font-weight: 600; border-radius: var(--radius-md); }
        .magicapp-link:hover { background: #2d5a87; }
        .magicapp-link svg { width: 16px; height: 16px; }
        .feedback-link { display: inline-flex; align-items: center; gap: 6px; padding: 10px 16px; color: var(--text-medium); text-decoration: none; font-size: 13px; font-weight: 500; border: 1px solid var(--border-light); border-radius: var(--radius-md); transition: all 0.2s; }
        .feedback-link:hover { border-color: var(--jia-purple); color: var(--jia-purple); background: var(--bg-light); }
        .feedback-link svg { width: 14px; height: 14px; }
        .modal-footer-left { display: flex; align-items: center; gap: 16px; flex-wrap: wrap; }
        .modal-footer-right { display: flex; align-items: center; gap: 12px; }
        
        .panel-info { margin-bottom: 28px; }
        .panel-info h3 { font-size: 16px; font-weight: 600; color: var(--text-dark); margin-bottom: 16px; display: flex; align-items: center; gap: 8px; }
        .panel-info h3 svg { width: 20px; height: 20px; color: var(--jia-purple); }
        .panel-members { display: flex; flex-wrap: wrap; gap: 10px; }
        .panel-member { display: inline-flex; align-items: center; padding: 8px 14px; background: var(--bg-light); border-radius: 100px; font-size: 14px; color: var(--text-medium); border: 1px solid var(--border-light); }
        .panel-member.chair { background: var(--primary-blue); color: var(--white); border-color: var(--primary-blue); }
        .info-item { display: flex; gap: 12px; margin-bottom: 16px; padding: 16px; background: var(--bg-light); border-radius: var(--radius-md); }
        .info-item:last-child { margin-bottom: 0; }
        .info-icon { flex-shrink: 0; width: 40px; height: 40px; background: var(--white); border-radius: var(--radius-sm); display: flex; align-items: center; justify-content: center; border: 1px solid var(--border-light); }
        .info-icon svg { width: 20px; height: 20px; color: var(--jia-purple); }
        .info-content { flex: 1; }
        .info-label { font-size: 12px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; color: var(--text-light); margin-bottom: 4px; }
        .info-value { font-size: 15px; color: var(--text-dark); }
        
        footer { background: var(--primary-blue); padding: 60px 24px 30px; color: var(--white); }
        .footer-container { max-width: 1200px; margin: 0 auto; }
        .footer-grid { display: grid; grid-template-columns: 2fr 1fr 1fr 1fr; gap: 48px; margin-bottom: 48px; }
        .footer-brand h3 { font-family: 'Source Serif 4', Georgia, serif; font-size: 20px; font-weight: 600; margin-bottom: 16px; }
        .footer-brand p { font-size: 14px; color: rgba(255,255,255,0.7); line-height: 1.7; }
        .footer-column h4 { font-size: 14px; font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; margin-bottom: 16px; }
        .footer-column a { display: block; color: rgba(255,255,255,0.7); text-decoration: none; font-size: 14px; padding: 6px 0; }
        .footer-column a:hover { color: var(--white); }
        .footer-bottom { padding-top: 30px; border-top: 1px solid rgba(255,255,255,0.1); text-align: center; }
        .footer-copyright { font-size: 13px; color: rgba(255,255,255,0.5); }
        
        @media (max-width: 768px) {
            .recommendations-grid { grid-template-columns: 1fr; }
            .footer-grid { grid-template-columns: 1fr; gap: 32px; }
            .page-header-content { flex-direction: column; align-items: flex-start; }
            .modal-content { max-height: 100vh; border-radius: 0; }
            .modal-header, .modal-body, .modal-footer { padding-left: 20px; padding-right: 20px; }
            .modal-tabs { padding: 0 16px; }
            .modal-tab { padding: 14px 16px; font-size: 13px; }
        }
    
        /* Evidence List Styles */
        .evidence-list { list-style: none; padding: 0; margin: 0; }
        .evidence-list li { padding: 10px 0; border-bottom: 1px solid var(--border-light); }
        .evidence-list li:last-child { border-bottom: none; }
        .evidence-list li::before { content: "â€¢"; color: var(--jia-purple); font-weight: bold; margin-right: 10px; }
        .evidence-list a { color: var(--jia-purple); text-decoration: none; font-weight: 500; }
        .evidence-list a:hover { text-decoration: underline; }
    
    
    /* Reference styling */
    sup a {
        color: #6b21a8;
        text-decoration: none;
        font-weight: 500;
        padding: 0 1px;
    }
    sup a:hover {
        color: #9333ea;
        text-decoration: underline;
    }

    </style>
    
    <script async src="https://www.googletagmanager.com/gtag/js?id=G-XQKQVSHVS5"></script>
    <script>
        window.dataLayer = window.dataLayer || [];
        function gtag(){dataLayer.push(arguments);}
        gtag('js', new Date());
        gtag('config', 'G-XQKQVSHVS5');
    </script>
</head>
<body>
    <header>
        <div class="header-top">
            <div class="header-top-content">
                <a href="https://anzmusc.org" target="_blank">ANZMUSC</a>
                <a href="https://rheumatology.org.au" target="_blank">Australian Rheumatology Association</a>
                <a href="https://musculoskeletal.cochrane.org" target="_blank">Cochrane Musculoskeletal</a>
            </div>
        </div>
        <div class="header-main">
            <a href="../" class="logo">
                <img src="../anzmusc-logo-header.png" alt="ANZMUSC" class="logo-image">
                <div class="logo-text">
                    <div class="logo-title">Australian Living Guidelines</div>
                    <div class="logo-subtitle">Evidence-Based Rheumatology Recommendations</div>
                </div>
            </a>
            <nav>
                <div class="nav-item">
                    <a href="#" class="nav-link">Guidelines <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg></a>
                    <div class="dropdown">
                        <a href="../adult/">Adult Inflammatory Arthritis</a>
                        <a href="../jia/">Juvenile Idiopathic Arthritis</a>
                    </div>
                </div>
                <div class="nav-item">
                    <a href="#" class="nav-link">About <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg></a>
                    <div class="dropdown">
                        <a href="../how-to-use.html">How to Use These Guidelines</a>
                        <a href="../who-we-are.html">Who We Are</a>
                        <a href="../panellists.html">Panel Members</a>
                        <a href="../methodology.html">Methodology</a>
                        <a href="../funding.html">Funding & Support</a>
                        <a href="../coi.html">Conflicts of Interest</a>
                    </div>
                </div>
                <div class="nav-item">
                    <a href="#" class="nav-link">Resources <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.23 7.21a.75.75 0 011.06.02L10 11.168l3.71-3.938a.75.75 0 111.08 1.04l-4.25 4.5a.75.75 0 01-1.08 0l-4.25-4.5a.75.75 0 01.02-1.06z" clip-rule="evenodd"/></svg></a>
                    <div class="dropdown">
                        <a href="../abbreviations.html">Abbreviations</a>
                        <a href="../media.html">Media</a>
                        <a href="../publications.html">Publications</a>
                    </div>
                </div>
                <a href="../contact.html" class="nav-link">Contact</a>
            </nav>
        </div>
    </header>

    <section class="hero">
        <div class="hero-content">
            <h1>Evidence-based living recommendations for the management of juvenile idiopathic arthritis</h1>
            <p class="hero-description">Helping Australian clinicians and families make informed decisions about the management of JIA in children and young people.</p>
            <div class="hero-badges">
                <span class="hero-badge"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M16.403 12.652a3 3 0 000-5.304 3 3 0 00-3.75-3.751 3 3 0 00-5.305 0 3 3 0 00-3.751 3.75 3 3 0 000 5.305 3 3 0 003.75 3.751 3 3 0 005.305 0 3 3 0 003.751-3.75zm-2.546-4.46a.75.75 0 00-1.214-.883l-3.483 4.79-1.88-1.88a.75.75 0 10-1.06 1.061l2.5 2.5a.75.75 0 001.137-.089l4-5.5z" clip-rule="evenodd"/></svg> NHMRC Approved</span>
                <span class="hero-badge"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm.75-13a.75.75 0 00-1.5 0v5c0 .414.336.75.75.75h4a.75.75 0 000-1.5h-3.25V5z" clip-rule="evenodd"/></svg> Living Guideline</span>
                <span class="hero-badge"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> 10 Recommendations</span>
            </div>
            <a href="#recommendations" class="hero-cta">Browse Recommendations <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M2 10a.75.75 0 01.75-.75h12.59l-2.1-1.95a.75.75 0 111.02-1.1l3.5 3.25a.75.75 0 010 1.1l-3.5 3.25a.75.75 0 11-1.02-1.1l2.1-1.95H2.75A.75.75 0 012 10z" clip-rule="evenodd"/></svg></a>
        </div>
    </section>

    <main class="main-content" id="recommendations">
        <div class="content-container">
            <div class="filter-section">
                <div class="search-container">
                    <svg class="search-icon" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M9 3.5a5.5 5.5 0 100 11 5.5 5.5 0 000-11zM2 9a7 7 0 1112.452 4.391l3.328 3.329a.75.75 0 11-1.06 1.06l-3.329-3.328A7 7 0 012 9z" clip-rule="evenodd"/></svg>
                    <input type="text" class="search-input" id="search-input" placeholder="Search recommendations...">
                    <button class="search-clear" id="search-clear" onclick="clearSearch()">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" width="14" height="14"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg>
                    </button>
                </div>
                
                <div class="filter-label">Filter by Topic</div>
                <div class="tag-filters">
                    <button class="tag-filter" data-tag="csdmards">csDMARDs</button>
                    <button class="tag-filter" data-tag="bdmards">bDMARDs</button>
                    <button class="tag-filter" data-tag="tsdmards">tsDMARDs</button>
                    <button class="tag-filter" data-tag="methotrexate">Methotrexate</button>
                    <button class="tag-filter" data-tag="glucocorticoids">Glucocorticoids</button>
                    <button class="tag-filter" data-tag="tapering">Tapering</button>
                    <button class="tag-filter" data-tag="uveitis">Uveitis</button>
                    <button class="tag-filter" data-tag="injection">Injection</button>
                    <button class="tag-filter" data-tag="non-pharmacological">Non-pharmacological</button>
                </div>
            </div>

            <div class="recommendations-grid" id="recommendations-grid">

                <div class="recommendation-card" data-tags="csdmards,methotrexate,leflunomide" onclick="openModal('jia-rec-1')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">DMARD therapy</div>
                            <div class="card-title">Methotrexate for juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with juvenile idiopathic arthritis requiring a systemic disease modifying anti-rheumatic drug, consider using methotrexate as initial therapy at a dose of 15mg/m2 once a week (maximum dose of 25mg per week).</p>
                        <div class="card-tags"><span class="card-tag">csDMARDs</span><span class="card-tag">Methotrexate</span><span class="card-tag">Leflunomide</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="csdmards,methotrexate" onclick="openModal('jia-rec-2')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">DMARD therapy</div>
                            <div class="card-title">Subcutaneous methotrexate versus oral methotrexate for juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with juvenile idiopathic arthritis, initial treatment with oral methotrexate is often appropriate. However, we conditionally recommend consideration of subcutaneous administration over oral administration in some circumstances.</p>
                        <div class="card-tags"><span class="card-tag">csDMARDs</span><span class="card-tag">Methotrexate</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="bdmards,tsdmards,uveitis" onclick="openModal('jia-rec-3')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Uveitis</div>
                            <div class="card-title">Biologic and targeted synthetic disease modifying anti-rheumatic drugs for JIA-associated uveitis with inadequate response to methotrexate</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with JIA-associated uveitis who have not responded to methotrexate, b/tsDMARDs should be considered. Adalimumab is recommended over other b/tsDMARDs. Etanercept is not recommended.</p>
                        <div class="card-tags"><span class="card-tag">bdDMARDs</span><span class="card-tag">tsDMARDs</span><span class="card-tag">Uveitis</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="csdmards,tapering" onclick="openModal('jia-rec-4')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Conventional synthetic DMARD (csDMARD) dose reduction or discontinuation for juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with juvenile idiopathic arthritis who have experienced a sustained period of low or absent disease activity, and in whom the current or potential adverse effects of treatment outweigh the potential risk and impact of disease flare, consider a trial of dose reduction or discontinuation of csDMARDs.</p>
                        <div class="card-tags"><span class="card-tag">csDMARDs</span><span class="card-tag">Tapering</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="bdmards,tsdmards,tapering" onclick="openModal('jia-rec-5')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Dose Reduction</div>
                            <div class="card-title">Biologic or targeted synthetic DMARD (b/tsDMARD) dose reduction or discontinuation for juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with juvenile idiopathic arthritis who have experienced a sustained period of inactive disease, and in whom the current or potential adverse effects of treatment outweigh the potential risk and impact of disease flare, consider a trial of dose reduction or discontinuation of b/tsDMARDs.</p>
                        <div class="card-tags"><span class="card-tag">bdDMARDs</span><span class="card-tag">tsDMARDs</span><span class="card-tag">Tapering</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="glucocorticoids" onclick="openModal('jia-rec-6')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Glucocorticoids</div>
                            <div class="card-title">Short-term adjunctive induction glucocorticoids for non-systemic juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people starting a disease modifying anti-rheumatic drug for non-systemic juvenile idiopathic arthritis, we conditionally recommend the short-term use of glucocorticoids for those who are likely to benefit most, including those with prominent pain or extensive inflammatory disease. A clear plan for tapering and discontinuation should be established when using glucocorticoids.</p>
                        <div class="card-tags"><span class="card-tag">Glucocorticoids</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="glucocorticoids,injection" onclick="openModal('jia-rec-7')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Intra-articular Therapies</div>
                            <div class="card-title">Choice of intra-articular glucocorticoid</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with juvenile idiopathic arthritis receiving intra-articular glucocorticoid injection, we conditionally recommend use of triamcinolone hexacetonide in preference to other intra-articular glucocorticoid preparations.</p>
                        <div class="card-tags"><span class="card-tag">Glucocorticoids</span><span class="card-tag">Injection</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="glucocorticoids,injection,anaesthesia" onclick="openModal('jia-rec-8')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Intra-articular Therapies</div>
                            <div class="card-title">Use of anaesthesia for intra-articular injection</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with juvenile idiopathic arthritis receiving intra-articular joint injection, consider use of topical and/or injectable anaesthesia based on a shared decision between patient, carer and clinician.</p>
                        <div class="card-tags"><span class="card-tag">Glucocorticoids</span><span class="card-tag">Injection</span><span class="card-tag">Anaesthesia</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="non-pharmacological,orthoses" onclick="openModal('jia-rec-9')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Non-pharmacological</div>
                            <div class="card-title">Foot orthoses in children and young people with juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-against"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4 10a.75.75 0 01.75-.75h10.5a.75.75 0 010 1.5H4.75A.75.75 0 014 10z" clip-rule="evenodd"/></svg></div>
                            <span class="strength-label">Conditional<br/>Against</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">Do not routinely use foot orthoses in children and young people with JIA. </p>
                        <div class="card-tags"><span class="card-tag">Non-pharmacological</span><span class="card-tag">Orthoses</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>

                <div class="recommendation-card" data-tags="non-pharmacological,exercise" onclick="openModal('jia-rec-10')">
                    <div class="card-header">
                        <div>
                            <div class="card-category">Non-pharmacological</div>
                            <div class="card-title">Exercise therapy in children and young people with juvenile idiopathic arthritis</div>
                        </div>
                        <div class="card-strength">
                            <div class="strength-indicator conditional-for"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10.75 4.75a.75.75 0 00-1.5 0v4.5h-4.5a.75.75 0 000 1.5h4.5v4.5a.75.75 0 001.5 0v-4.5h4.5a.75.75 0 000-1.5h-4.5v-4.5z"/></svg></div>
                            <span class="strength-label">Conditional<br/>For</span>
                        </div>
                    </div>
                    <div class="card-body">
                        <p class="card-recommendation">In children and young people with JIA who have persistent symptoms or functional limitation despite optimal medical therapy, we conditionally recommend an exercise therapy programme that is tailored t...</p>
                        <div class="card-tags"><span class="card-tag">Non-pharmacological</span><span class="card-tag">Exercise</span></div>
                    </div>
                    <div class="card-footer">
                        <span class="card-link">View details <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M3 10a.75.75 0 01.75-.75h10.638L10.23 5.29a.75.75 0 111.04-1.08l5.5 5.25a.75.75 0 010 1.08l-5.5 5.25a.75.75 0 11-1.04-1.08l4.158-3.96H3.75A.75.75 0 013 10z" clip-rule="evenodd"/></svg></span>
                        <span class="card-updated">Updated October 2025</span>
                    </div>
                </div>
            </div>
            <div id="no-results" class="no-results">
                <h3>No recommendations found</h3>
                <p>Try adjusting your search or filters</p>
            </div>
        </div>
    </main>


    <div class="modal-overlay" id="modal-jia-rec-1">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">DMARD therapy</div>
                    <h2 class="modal-title">Methotrexate for juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-1', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-1', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-1', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-1', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-1', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-1-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with juvenile idiopathic arthritis requiring a systemic disease modifying anti-rheumatic drug, consider using methotrexate as initial therapy at a dose of 15mg/m2 once a week (maximum dose of 25mg per week).</p></div>
                    <div class="remark-box"><p>Methotrexate is preferred over leflunomide unless specific contraindications to methotrexate are present.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>While the certainty of evidence was generally low, the panel agreed that the included randomised controlled trial evidence generally demonstrated some efficacy for methotrexate in the treatment of juvenile idiopathic arthritis (JIA). The panel additionally considered other data from a comparative trial comparing two different doses of methotrexate and observational data that support the use of methotrexate. Internationally, methotrexate is generally regarded as a suitable initial treatment for many patients with JIA <sup><a href="https://doi.org/10.1002/acr.24839" target="_blank" title="Onel et al. (2021)">53</a></sup><sup><a href="https://doi.org/10.1002/acr.23870" target="_blank" title="Ringold et al. (2019)">54</a></sup><sup><a href="https://pubmed.ncbi.nlm.nih.gov/15688190/" target="_blank" title="Niehues et al.">55</a></sup>. Use of methotrexate has been observed to drastically improve outcomes of JIA over recent decades <sup><a href="https://doi.org/10.1038/nrrheum.2014.212" target="_blank" title="Hinze et al. (2015)">52</a></sup>.</p>
<p>From a practical perspective, the panel did not identify any major barriers such as cost, availability or acceptability to using methotrexate.</p>
<p>Methotrexate related side-effects such as nausea were discussed and noted to be significant for many patients. However, the panel agreed that methotrexate should still be considered as initial therapy in the context of a treat-to-target approach to care where alternative treatments are available in the event of methotrexate intolerance.</p>
<p>The panel also considered that in most cases methotrexate is favoured over leflunomide as the initial choice of DMARD. This was based on the findings of a head-to-head RCT which demonstrated superior efficacy of methotrexate versus leflunomide (as measured by pedACR30 and pedACR70) and a comparable safety profile <sup><a href="https://pubmed.ncbi.nlm.nih.gov/15843668/" target="_blank" title="Silverman et al.">40</a></sup>.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-1-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>The evidence considered by the panel for this recommendation specifically relates to the use of methotrexate in children and young people with juvenile idiopathic arthritis (JIA). The evidence is drawn from five RCTs; three compared methotrexate to placebo (<sup><a href="http://medind.nic.in/jaa/t03/i2/jaat03i2p30.pdf" target="_blank" title="Bharadwaj et al.">42</a></sup>, <sup><a href="https://pubmed.ncbi.nlm.nih.gov/1549149/" target="_blank" title="Giannini et al.">38</a></sup>, <sup><a href="https://pubmed.ncbi.nlm.nih.gov/10943876/" target="_blank" title="Woo et al.">41</a></sup>), one compared methotrexate to leflunomide (<sup><a href="https://pubmed.ncbi.nlm.nih.gov/15843668/" target="_blank" title="Silverman et al.">40</a></sup>) and one examined concomitant administration of methotrexate in patients undergoing intra-articular steroid injections <sup><a href="https://doi.org/10.1016/S0140-6736(17)30065-X" target="_blank" title="Ravelli et al.">39</a></sup>.</p>
<p>In children and young people with juvenile idiopathic arthritis, treatment with methotrexate for up to 12 months:</p>
<p>Compared with placebo, oral methotrexate (5-15mg/mÂ²/week):</p>
<ul>
<li>May increase the number of children and young people achieving treatment response</li>
<li>May have little or no effect on the number of children and young people who report treatment success, and on pain</li>
<li>May have little to no effect on the number of children and young people reporting serious adverse events, and on the number of withdrawals due to adverse events</li>
<li>No studies were found that assessed the number of children and young people with clinically inactive disease or mean function</li>
</ul>
<p>Compared with intra-articular glucocorticoid injection alone, treatment with oral methotrexate (15mg/mÂ²/week) plus intra-articular glucocorticoid injection, specifically in children and young people with oligoarticular JIA:</p>
<ul>
<li>May have little or no effect on the number of children and young people with clinically inactive disease</li>
<li>May have little or no effect on the number of children and young people reporting withdrawals due to adverse events</li>
<li>We are uncertain of the effect on the number of children and young people reporting serious adverse events, as no participants reported this event</li>
<li>No studies were found that assessed the number of people achieving treatment response, mean function, mean pain or mean global assessment of wellbeing</li>
</ul>
<p>Compared with leflunomide, treatment with oral methotrexate (0.5mg/kg/week):</p>
<ul>
<li>May increase the number of children and young people achieving treatment response</li>
<li>May have little or no effect on mean function and mean participant global assessment of wellbeing</li>
<li>May have little or no effect on the number of serious adverse events, and on the number of withdrawals due to adverse events</li>
<li>No studies were found that assessed number of children and young people with clinically inactive disease or mean pain</li>
</ul>
<p>The panel also considered that the doses of methotrexate that were tested in some of the trials may not reflect contemporary clinical practice. This may have reduced the likelihood of detecting a true benefit of methotrexate if  one exists. The included studies tested doses of 5 or 10 mg/m2/week (n=1) <sup><a href="https://pubmed.ncbi.nlm.nih.gov/1549149/" target="_blank" title="Giannini et al.">38</a></sup>, 10 mg/m2/week (n=1)<sup><a href="http://medind.nic.in/jaa/t03/i2/jaat03i2p30.pdf" target="_blank" title="Bharadwaj et al.">42</a></sup>, 0.5mg/kg/week (n=1) <sup><a href="https://pubmed.ncbi.nlm.nih.gov/15843668/" target="_blank" title="Silverman et al.">40</a></sup> and 15 mg/m2/week (n=2) <sup><a href="https://doi.org/10.1016/S0140-6736(17)30065-X" target="_blank" title="Ravelli et al.">39</a></sup><sup><a href="https://pubmed.ncbi.nlm.nih.gov/10943876/" target="_blank" title="Woo et al.">41</a></sup>. The panel considered that only the latter two trials used methotrexate doses that would be considered contemporary standard practice for managing JIA. Secondly, in contrast to contemporary practice the trials also did not include an allowance for increasing the dose of methotrexate if needed to improve response in those with relatively low dosing, a strategy that has been found to be beneficial <sup><a href="https://pubmed.ncbi.nlm.nih.gov/15248217/" target="_blank" title="Ruperto et al.">43</a></sup>.  The 0.5mg/kg/week dosing of one of the studies <sup><a href="https://pubmed.ncbi.nlm.nih.gov/15843668/" target="_blank" title="Silverman et al.">40</a></sup> is no longer recommended in contemporary practice for methotrexate dosing due to improved precision with body surface area dosing in the paediatric population. However, it can be regarded as achieving comparable therapeutic dosing as 15 mg/m2/week with respect to efficacy <sup><a href="https://doi.org/10.3899/jrheum.090826" target="_blank" title="Becker et al.">57</a></sup>.</p>
<p>The panel considered that there are other data suggesting that methotrexate may be an efficacious treatment for JIA, albeit this evidence is of low certainty.  Observational data are likely to overestimate the true benefits of treatment and need to be interpreted with caution. A 2010 retrospective analysis comparing oral vs subcutaneous methotrexate by Klein and colleagues reported that 72% (oral methotrexate at 0.4 mg/kg/week) and 73% (subcutaneous methotrexate at 0.42 mg/kg/week) of patients obtained an ACR30 response by six months <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup>. Similarly, a 2014 randomised controlled trial comparing two different doses of methotrexate found  a 72% ACR30 response rate in methotrexate treated children with a subcutaneous methotrexate at 15 mg/m2/week) at 6 months in a population of patients with JIA who was unresponsive to a lower (8-12.5mg/m2/week) dose of methotrexate <sup><a href="https://pubmed.ncbi.nlm.nih.gov/15248217/" target="_blank" title="Ruperto et al.">43</a></sup>.</p>
<p>The panel also acknowledged that methotrexate has been proven to be an effective treatment for diseases similar to JIA. In adults with rheumatoid arthritis, methotrexate has a substantial clinical benefit compared to placebo <sup><a href="https://doi.org/10.1002/14651858.CD000957.pub2" target="_blank" title="Lopez-Olivo et al.">45</a></sup>. Methotrexate is also an effective medication for other childhood rheumatic diseases such as juvenile dermatomyositis <sup><a href="https://doi.org/10.1016/S0140-6736(15)01021-1" target="_blank" title="Ruperto et al.">46</a></sup>.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>The certainty of evidence was low for the majority of outcomes for all three comparisons.</p>
<p>Evidence from three trials comparing methotrexate with placebo was low certainty for treatment response, participant global assessment, mean improvement in pain, serious adverse events, and withdrawals due to adverse events. All outcomes were downgraded once for indirectness due to dosing of methotrexate in two of the three trials that are lower than current contemporary practice, and dissimilar or unexpected outcome measures: different measures of treatment response were reported across trials, ie, none of the trials used the pedACR70; one trial used a dichotomous measure for global assessment rather than a continuous scale that is more commonly used in practice <sup><a href="https://pubmed.ncbi.nlm.nih.gov/10943876/" target="_blank" title="Woo et al.">41</a></sup>; and use of a pain subscale instead of overall pain <sup><a href="https://pubmed.ncbi.nlm.nih.gov/1549149/" target="_blank" title="Giannini et al.">38</a></sup>. All outcomes were downgraded a second time for imprecision due to low participant numbers and/or a small number of events. No studies assessed clinically inactive disease or mean function.</p>
<p>Evidence from a single trial comparing methotrexate and intra-articular steroids with intra-articular steroids alone provided low certainty evidence for proportion with clinically inactive disease and withdrawals due to adverse events and very low certainty evidence for serious adverse events . Evidence was downgraded once due to the risk of performance and detection bias for all outcomes, once for imprecision for proportion with clinically inactive disease, and downgraded once for imprecision due to very low event rates for withdrawals due to adverse events and twice for imprecision due to no events with serious adverse events.  This study did not assess treatment response, function, pain or participant global assessment.</p>
<p>There was low certainty evidence regarding treatment response, mean function, participant global assessment, serious adverse events and withdrawal due to adverse events in the study comparing methotrexate with leflunomide. The evidence was downgraded twice for imprecision due to a small number of events and a low number of participants. This study did not assess proportion with clinically inactive disease or pain.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">No substantial variability expected</span></div><div class="etd-domain-text"><p>There are limited data on patient and carer preferences and values in JIA. A recent thematic analysis showed that both the treatments and complications of JIA have a significant impact on the quality of life and emotional well-being of children and young people with JIA <sup><a href="https://doi.org/10.1186/s12969-017-0189-6" target="_blank" title="Sen et al.">23</a></sup>. Commencing immunomodulatory treatment in children can be quite confronting for patients and their carers. Methotrexate can cause particular concern given its use as a cytotoxic drug at higher doses and infrequent but potentially severe adverse effects. However, the potential impact of untreated JIA was not lost on the panel, with an understanding of the potential for chronic pain, joint damage, occupational impairment and disability as potential outcomes when systemic immunomodulation with methotrexate and other therapies are not offered.</p>
<p>Overall, when considering risks and benefits, the panel felt that most people would be likely to choose methotrexate given the potential for improving symptoms and despite the low risk of harms.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Conventional disease modifying anti-rheumatic drugs(csDMARDs) including methotrexate are considerably cheaper than biologic DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs). Oral methotrexate is very affordable in Australia while parenteral methotrexate is more expensive and not currently subsidised by the Pharmaceutical Benefits Scheme (PBS) for the indication of JIA.</p>
<p>Methotrexate is also the most commonly prescribed csDMARD in the management of JIA and is deemed an appropriate first-line treatment option for the condition. A recent RCT comparing different treat to target strategies demonstrated similar outcomes can be achieved using first line methotrexate compared to first line methotrexate combined with a bDMARD  <sup><a href="https://doi.org/10.1136/annrheumdis-2018-213902" target="_blank" title="Hissink et al.">47</a></sup>.</p>
<p>The panel agreed that oral methotrexate is a cost and resource efficient intervention, particularly when alternative treatments such as bDMARDs and tsDMARDs are considered.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered equity issues using the PROGRESS-Plus framework (place of residence, race/ ethnicity/culture/language, occupation, gender/ sex, religion, education, socioeconomic status, and social capital; the Plus components refer to personal characteristics associated with discrimination such as disability, features of relationships, and time-dependent relationships) and health literacy <sup><a href="https://doi.org/10.1016/j.jclinepi.2013.08.005" target="_blank" title="O'Neill et al.">18</a></sup>.</p>
<p>Financial constraints, the absence of specialists to supervise the use of drugs in clinical practice and drug unavailability have all been identified as potential major barriers to treatment of JIA in Australasia <sup><a href="https://doi.org/10.1186/s12969-021-00498-1" target="_blank" title="Tangcheewinsirikul et al.">26</a></sup>. The provision of tertiary paediatric rheumatology care in Australia is relatively constrained to major cities <sup><a href="https://doi.org/10.1111/1756-185X.12802" target="_blank" title="Cox et al.">10</a></sup>. Access to a paediatric rheumatologist is a key determinant of high-quality care and it is unlikely that treatment with methotrexate would be feasible without input from a metropolitan treating unit.</p>
<p>It should also be noted that some members of the Australian community may not have access to Medicare (e.g. refugees). These people may experience additional barriers to the use of methotrexate (including the cost of medical appointments, medications, pathology), which may contribute to additional health inequity.</p>
<p>Despite the above potential contributors to inequity, the panel did not feel that treatment with methotrexate would have a significant effect on equity for most children and young people living in Australia with JIA. Given the low overall cost of methotrexate, the widespread accessibility of it through most Australian pharmacies, and the efforts made by tertiary paediatric rheumatology centres to broaden their scope of practice to achieve subspecialty service access to those patients with JIA in regional and remote communities, the overall potential for inequity currently was deemed low.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that methotrexate is likely to be generally acceptable to clinicians and policymakers although the acceptability may vary between patients and their carers.</p>
<p>It was agreed that most patients and their carers recognise the importance of adequately treating JIA. However, methotrexate toxicity is a major issue for many patients with JIA. Gastrointestinal symptoms, such as nausea and vomiting, can be particularly troublesome. Gastrointestinal side-effects related to methotrexate administration are often highlighted by patients as a major issue that can be impactful on their quality of life (<sup><a href="https://doi.org/10.1186/s12969-015-0052-6" target="_blank" title="Mulligan et al.">48</a></sup>, <sup><a href="https://doi.org/10.1002/art.30367" target="_blank" title="BulatoviÄ‡ et al.">49</a></sup>, <sup><a href="https://doi.org/10.1186/s12969-017-0180-2" target="_blank" title="Falvey et al.">50</a></sup>, <sup><a href="https://doi.org/10.1186/s12969-019-0366-x" target="_blank" title="Renton et al.">51</a></sup>).</p>
<p>Several members of the panel felt that there may be varied acceptability among key stakeholders because of the potential for gastrointestinal side effects and other adverse events. While some children and young people will experience side effects with methotrexate, the panel considered that the alternative of untreated JIA would be less acceptable for most patients and their carers.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Methotrexate is widely available in most pharmacies in Australia and the oral form in particular is unrestricted on the PBS and of modest cost. Subcutaneous methotrexate is also widely available in Australia and accessible to children and young people with JIA through various means. It is a medication all paediatric rheumatologists and clinicians regularly managing patients with JIA are comfortable in prescribing and monitoring.</p>
<p>In the context of the above, the panel unanimously agreed that methotrexate is a feasible first line treatment for patients needing a DMARD.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-1-practical">
                    <div class="content-section">
                        <ul>
<li>A treat-to-target approach within a shared decision-making framework is recommended for all patients with juvenile idiopathic arthritis (JIA), including with respect to escalation of therapy to a disease modifying anti-rheumatic drug such as methotrexate.</li>
<li>Upon introduction of methotrexate into the treatment regimen of a young person with JIA, blood tests are recommended at intervals to monitor for adverse events such as liver enzyme derangement or low cell counts. A full blood count, renal function and liver function tests are recommended prior to commencement, within the first one to two months of commencing methotrexate and three to four monthly thereafter. Significant anomalies may warrant closer laboratory monitoring, dose adjustment or discontinuation <sup><a href="https://doi.org/10.1002/acr.24839" target="_blank" title="Onel et al. (2021)">53</a></sup>.</li>
<li>Oral folic acid supplementation is recommended in conjunction with methotrexate to improve tolerability. There is currently no consensus on ideal dosing of folic acid in JIA <sup><a href="https://doi.org/10.1007/s00296-013-2696-1" target="_blank" title="Amarilyo et al.">58</a></sup>. One commonly used dosing regime for folic acid is 1mg daily (except on day of methotrexate administration).</li>
<li>Subcutaneous methotrexate may be more appropriate for some patients due to higher bioavailability and improved tolerability compared to oral methotrexate treatment. Subcutaneous methotrexate should be considered in patients with inadequate response to oral methotrexate or who are experiencing gastrointestinal side effects on oral methotrexate.</li>
<li>Inadequate response despite adequate exposure or intolerance to methotrexate should prompt early consideration of adjusting therapy (on a 3 monthly basis) in keeping with a treat-to-target approach <sup><a href="https://doi.org/10.1136/annrheumdis-2019-216843" target="_blank" title="Klein et al.">56</a></sup>. This is especially important for JIA with a polyarticular disease course, or which is affecting joints at higher risk of deformity or impairment of function (such as the wrist, ankle and/or cervical spine).</li>
<li>The Australian Rheumatology Association provides patient information sheets for those commencing DMARDs, including for <a href="https://rheumatology.org.au/patient/Documents/Methotrexate_2022.pdf" target="_blank">methotrexate</a>.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-1-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 2: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis, is methotrexate safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/159tO_-BQGOq93XZWPcKvxqiaG7aI_aGY/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-1-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Prof Rachelle Buchbinder (Chair)</span>
<span class="panel-member chair">Dr Sue Brennan (Facilitator)</span>
<span class="panel-member">Catherine Booth</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Dr Jessica McGrath</span>
<span class="panel-member">Dr Jane Munro</span>
<span class="panel-member">Ishani Perera</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Tracy Rose</span>
<span class="panel-member">Emily Sheridan</span>
<span class="panel-member">Dr Joachim Tan</span>
<span class="panel-member">Dr Samuel Whittle</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">24 March 2022</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Methotrexate%20for%20children%20and%20adolescents%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240269" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-2">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">DMARD therapy</div>
                    <h2 class="modal-title">Subcutaneous methotrexate versus oral methotrexate for juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-2', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-2', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-2', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-2', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-2', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-2-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with juvenile idiopathic arthritis, initial treatment with oral methotrexate is often appropriate. However, we conditionally recommend consideration of subcutaneous administration over oral administration in some circumstances.</p></div>
                    <div class="remark-box"><p>Subcutaneous administration of methotrexate is conditionally recommended when optimal bioavailability is desired, such as in those with extensive inflammatory disease, or when a patient has experienced or is perceived to be at high risk of intolerance to oral methotrexate.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>There were no RCTs that compared subcutaneous to oral MTX in children and young people with JIA to help guide this recommendation. We therefore considered prospective registry-based observational studies to provide an evidence base for guiding our decision-making process. The evidence was considered very low certainty due to the high risk of bias for the efficacy outcomes and the very low adverse event rates. These studies were also not useful in providing guidance on other patient-relevant outcomes and patient preferences.</p>
<p>In making a recommendation, the panel also considered other important factors that may influence a decision regarding oral or parenteral MTX as described in the Evidence to Decision Framework. The panel agreed that the decision to start either oral or subcutaneous methotrexate should be made within a shared decision model between clinician and a patient and/or their carer. Factors that may influence this decision include previous experiences with subcutaneous medications, degree of disease activity, neurodevelopmental diagnoses such as autism, access to available support to safely administer methotrexate subcutaneously, and the willingness to administer injections.</p>
<p>This recommendation was also determined to be conditional due to the very low certainty of evidence based upon observational data only.</p>
<p>The lack of any high-quality evidence to guide this recommendation highlights the need for further research in this area, ideally in the form of comparative effectiveness RCTs.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-2-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>The evidence considered by the panel for this recommendation specifically relates to the use of either parenteral (subcutaneous or intramuscular) or oral methotrexate (MTX) in children and young people with juvenile idiopathic arthritis (JIA). We were unable to identify any randomised controlled trials (RCTs) directly comparing parenteral and oral MTX. Four prospective registry-based observational studies were identified. Three compared the initiation of either parenteral to oral MTX <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup><sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup><sup><a href="https://doi.org/10.1186/s12969-016-0099-z" target="_blank" title="Franova et al.">103</a></sup> and one determined the effect of switching from oral to parenteral MTX <sup><a href="https://pubmed.ncbi.nlm.nih.gov/14705239/" target="_blank" title="Alsufyani et al.">101</a></sup>. In the absence of RCT evidence, efficacy and safety outcomes from the observational studies were assessed.</p>
<p>Two studies reported American College of Rheumatology-pediatric (ACR-pedi) <sup><a href="https://doi.org/10.1002/1529-0131(199707)40:7%3C1202::AID-ART3%3E3.0.CO;2-R" target="_blank" title="Giannini et al.">105</a></sup> responses at thresholds of 30%, 50%, 70% and 90% improvement after six months of treatment with MTX <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup><sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup>. Neither study identified a difference in ACR-pedi-30/50/70 response. Only one study reported AC-pedi-90 response and suggested a minor benefit in favour of parenteral MTX treatment (37% vs 23%, odds ratio (OR) 1.97, 95% confidence interval (CI) 1.45 to 2.69) <sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup>.</p>
<p>Three studies reported on adverse events <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup><sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup><sup><a href="https://doi.org/10.1186/s12969-016-0099-z" target="_blank" title="Franova et al.">103</a></sup>. Adverse events leading to discontinuation were uncommon but found to be more frequently observed in patients using parenteral MTX in one study (11% vs 5%, OR 2.42, 95% CI 1.11 to 5.27) <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup> but there were no between-group differences in another study (16% vs 16%, OR 1.04, 95% CI 0.71 to 1.52) <sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup>. The third study noted a trend towards increased odds for MTX intolerance with the use of parenteral MTX but was not statistically significant (OR (95%CI)â€‰=â€‰2.44 (0.56;10.65), p=0.236<sup><a href="https://doi.org/10.1186/s12969-016-0099-z" target="_blank" title="Franova et al.">103</a></sup>.Severe adverse events (sAE) were reported in two studies and noted in less than 3% of all participants with no differences between the parenteral and oral MTX groups. Gastrointestinal symptoms, including nausea and vomiting, were assessed in three studies. One study identified a higher rate of these events in the parenteral MTX group (51.6% vs 35.1%, OR 1.97, 95% CI 1.48 to 2.61) <sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup> while two others did not identify a difference between groups <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup><sup><a href="https://doi.org/10.1186/s12969-016-0099-z" target="_blank" title="Franova et al.">103</a></sup>.</p>
<p>One study explored the effect of switching to parenteral MTX in those who have failed oral MTX due to inefficacy or intolerance <sup><a href="https://pubmed.ncbi.nlm.nih.gov/14705239/" target="_blank" title="Alsufyani et al.">101</a></sup>. Among 31 patients who switched, after 3 months of parenteral MTX treatment, 76% were classified as improved and 23% as not improved. Nine of the 11 patients with nausea had complete resolution of their symptoms after switching to parenteral methotrexate. The other two patients continued to have nausea on parenteral MTX but it was less severe and they were able to continue on MTX treatment. Four children developed transient laboratory changes (liver enzyme abnormalities, lymphopaenia) after switching, leading to temporary discontinuation in two.</p>
<p>Regarding the use of parenteral MTX, adult studies have demonstrated comparable pharmacokinetics of subcutaneous and intramuscular MTX <sup><a href="https://doi.org/10.1002/art.1780330112" target="_blank" title="Brooks et al.">106</a></sup>. However, subcutaneous administration may be more convenient and less painful and therefore intramuscular MTX is not currently recommended where parenteral treatment is indicated <sup><a href="https://doi.org/10.1002/art.1780330112" target="_blank" title="Brooks et al.">106</a></sup>.</p>
<p>The panel acknowledged the absence of RCTs for this question and the significant limitations of the registry-based study data. In the absence of potentially important trends favouring one mode of delivery of MTX to another based upon observational data, the panel unanimously agreed that it is likely that there is a small net benefit or little difference between using parenteral or oral methotrexate. It was recognised that the individual benefit is likely to vary significantly depending on multiple factors, including prior experience with methotrexate, age, comorbidities and disease severity.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very low</span></div><div class="etd-domain-text"><p>No RCTs were identified for this question.</p>
<p>The included observational trials were limited to prospectively collected registry data. Of the four included studies, all were deemed at high risk of detection bias as outcome assessors were not likely to have been blinded. Outcome measures were varied and reported outcomes were very limited, particularly in one of the four studies <sup><a href="https://doi.org/10.1186/s12969-016-0099-z" target="_blank" title="Franova et al.">103</a></sup>.</p>
<p>Findings from two of the larger observational trials suggested that patients treated with parenteral rather than oral MTX were more likely to have more severe disease indicating an important selection bias. Compared with the oral MTX groups, the parenteral MTX groups in both studies had higher rates of seropositivity, higher baseline joint counts and higher inflammatory markers <sup><a href="https://doi.org/10.1002/acr.21697" target="_blank" title="Klein et al.">44</a></sup><sup><a href="https://doi.org/10.5152/eurjrheum.2022.21090" target="_blank" title="Bakry et al.">102</a></sup>.</p>
<p>It was not possible to come to confident conclusions based upon the included data given the uncontrolled nature of the reports, differences in group baseline characteristics and variability of outcome measures that were used. Similarly, the included studies were not large enough to detect important adverse events.</p>
<p>The panel agreed that the level of evidence should be assessed as very low.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>There are limited data on patient and carer preferences and values in JIA. A recent thematic analysis showed that both the treatments and complications of JIA have a significant impact on the quality of life and emotional well-being of children and young people with JIA <sup><a href="https://doi.org/10.1186/s12969-017-0189-6" target="_blank" title="Sen et al.">23</a></sup>.</p>
<p>Parents of children and young people with JIA have strong preferences for treatments that reduce pain and improve daily functioning regardless of the potential adverse effects <sup><a href="https://doi.org/10.1002/acr.21698" target="_blank" title="Burnett et al.">74</a></sup>. Given that parenteral administration increases exposure to MTX <sup><a href="https://pubmed.ncbi.nlm.nih.gov/20149329/" target="_blank" title="TukovÃ¡ et al.">113</a></sup>, it may theoretically improve treatment response although this has not been demonstrated in controlled studies.</p>
<p>The panel highlighted the potential downsides of both oral and parenteral MTX. Injectable medications are a major factor in the overall treatment burden for some children and young people with JIA <sup><a href="https://doi.org/10.11124/JBIES-21-00139" target="_blank" title="Min et al.">108</a></sup><sup><a href="https://doi.org/10.1186/s12969-017-0189-6" target="_blank" title="Sen et al.">109</a></sup>. The panel acknowledged that despite issues with injectable medications, the potential to offset very problematic adverse effects, such as severe nausea, would be very important for some patients and their families. Anecdotal experience of much improved tolerability of subcutaneous rather than oral MTX for some patients was highlighted. Examples of improved tolerability ranged from improved medication associated nausea, improved anticipatory nausea, and avoidance of challenges with physically administering an oral medication with an unpleasant taste, particularly in very young children. Use of parenteral rather than oral MTX also provides more certainty that the entire dose that was prescribed was administered.</p>
<p>MTX associated gastrointestinal adverse events such as nausea are a major cause of morbidity <sup><a href="https://doi.org/10.1186/s12969-019-0366-x" target="_blank" title="Renton et al.">51</a></sup><sup><a href="https://doi.org/10.1016/j.pedn.2019.06.004" target="_blank" title="Khan et al.">107</a></sup>. The role of parenteral MTX in managing these symptoms is unclear. While bypassing the gastrointestinal tract may potentially help reduce the likelihood of such adverse effects, the higher absorption with parenteral dosing could theoretically increase these effects due to the increased bioavailability of the administered medication.</p>
<p>The panel agreed that there is likely to be significant variability in the relative importance that patients and families place on the potential benefits and harms of parenteral versus oral methotrexate.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>MTX in the form of a tablet is considerably cheaper than injectable MTX. At the time of writing, a 10mg tablet of MTX is priced at $1.62, while a 10mg pre-filled syringe is priced at $22.39 through the Australian Pharmaceutical Benefits Scheme (PBS). However, injectable MTX pre-filled syringes are not currently available to patients with JIA through the PBS. A submission to the Pharmaceutical Benefits Advisory Committee (PBAC) has requested the addition of injectable MTX to the PBS formulary for the indication of JIA and this decision is pending.</p>
<p>Some caregivers may feel uneasy about administering a weekly injection to their child, thus further increasing medical costs due to the need to attend a community health centre on a regular basis for the injections. Additionally, resources such as psychology input may be required to manage needle phobia and medical trauma more broadly.</p>
<p>It was acknowledged that the role of parenteral MTX in reducing the need for more expensive second line treatments such as bDMARDs has not been vigorously assessed.</p>
<p>The environmental effects of parenteral MTX are likely to be more detrimental when compared to oral MTX when factors such as manufacturing, packaging and responsible disposal of used syringes is considered.</p>
<p>The panel agreed that the minor resource issues pertaining to parenteral MTX are likely to be of little concern when considering the broader potential benefits but also appreciated several potential issues that may necessitate further investigation.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered equity issues using the PROGRESS-Plus framework (place of residence, race/ ethnicity/culture/language, occupation, gender/sex, religion, education, socioeconomic status, and social capital; the Plus components refer to personal characteristics associated with discrimination such as disability, features of relationships, and time-dependent relationships) and health literacy <sup><a href="https://doi.org/10.1016/j.jclinepi.2013.08.005" target="_blank" title="O'Neill et al.">18</a></sup>.</p>
<p>Financial constraints, the absence of specialists to supervise the use of drugs in clinical practice and drug unavailability have all been identified as potential major barriers to treatment of JIA in Australia <sup><a href="https://doi.org/10.1186/s12969-021-00498-1" target="_blank" title="Tangcheewinsirikul et al.">26</a></sup>.</p>
<p>Certain patient groups may have specific barriers in accessing parenteral MTX and the appropriate supports for its administration. The cost of parenteral MTX could be prohibitive for some patients. Patients from regional areas and those with poor health literacy may experience additional barriers to the successful initiation and administration of parenteral MTX. The panel provided several anecdotes of inappropriate parenteral administration (poor technique or inadvertent intra-muscular administration rather than subcutaneous injection) and treatment discontinuation among these groups. Patients with certain medical (developmental delay, others) or psychological comorbidities (autism spectrum disorder, anxiety, others) may have additional difficulties with using injectable medications.</p>
<p>Patients in certain health-care settings such as in rural areas may not have equitable access to appropriate training for the use of subcutaneous medications.</p>
<p>The panel agreed that there are likely to be important equity issues when recommending parenteral MTX.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Subcutaneous MTX is commonly used in Australia and comparable healthcare systems so is likely to be acceptable to treating medical teams.</p>
<p>While there are additional direct (medication price) and indirect (nursing support, sharps disposal) costs of parenteral MTX compared with oral MTX, potential health care and societal benefits may include improved treatment adherence (and secondary decrease in disease burden), and decreased reliance on second-line therapies including bDMARDs.</p>
<p>The acceptability to individual patients and their families is likely to vary significantly. This was well articulated by the panel using real world examples of patients with very strong preferences for one mode of administration or the other.</p>
<p>The panel agreed that parenteral MTX is likely to be largely acceptable to clinicians and policymakers, but it is very likely that the acceptability to children and their families would vary widely.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The out-of-pocket costs may be a factor in the feasibility of recommending parenteral MTX for some patients.</p>
<p>Similarly, the practicalities of administering a regular injectable medication will not be feasible for some patients.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-2-practical">
                    <div class="content-section">
                        <ul>
<li>The decision to start either oral or subcutaneous MTX should be made within a shared decision model between clinician and a patient and/or their carer. This decision will be contextually dependent on multiple factors including age, disease severity, comorbidities and personal preference.</li>
<li>A treat-to-target approach within a shared decision-making framework is recommended for all patients with juvenile idiopathic arthritis (JIA), including with respect to commencing a disease modifying anti-rheumatic drug such as MTX and its mode of administration.</li>
<li>Upon introduction of methotrexate into the treatment regimen of a young person with JIA, blood tests are recommended at intervals to monitor for adverse events such as liver enzyme derangement or low cell counts. A full blood count, renal function and liver function tests are recommended prior to commencement, within the first one to two months of commencing methotrexate and three to four monthly thereafter. Significant anomalies may warrant closer laboratory monitoring, dose adjustment or discontinuation <sup><a href="https://doi.org/10.1002/acr.24839" target="_blank" title="Onel et al. (2021)">53</a></sup>.</li>
<li>Oral folic acid supplementation is recommended in conjunction with methotrexate to improve tolerability. There is currently no consensus on ideal dosing of folic acid in JIA <sup><a href="https://doi.org/10.1007/s00296-013-2696-1" target="_blank" title="Amarilyo et al.">58</a></sup>. Two commonly used dosing regimens for folic acid are 1mg daily except on the day of methotrexate administration or 5mg the day before and/or after the day of methotrexate administration.</li>
<li>Where parenteral methotrexate is used, subcutaneous rather than intra-muscular administration is recommended.</li>
<li>The mode of administration of methotrexate should be reassessed at each clinical visit.</li>
<li>Appropriate counselling should be conducted prior to the commencement of parenteral or oral methotrexate. Patients undergoing treatment with parenteral methotrexate should have training on its administration by an experienced practitioner.</li>
<li>In keeping with a treat to target approach, inadequate response despite adequate exposure or intolerance to methotrexate regardless of mode of administration should prompt early consideration of adjusting therapy (on a three-monthly basis) <sup><a href="https://doi.org/10.1136/annrheumdis-2019-216843" target="_blank" title="Klein et al.">56</a></sup>.</li>
<li>Subcutaneous methotrexate can be administered via a pre-filled syringe device for injection or prepared from drawing up the correct volume from a vial.</li>
<li>The Australian Rheumatology Association provides patient information sheets for those commencing DMARDs, including for <a href="https://rheumatology.org.au/patient/Documents/Methotrexate_2022.pdf" target="_blank">methotrexate</a> and <a href="https://rheumatology.org.au/patient/Documents/Sharps-Disposal_2021.pdf" target="_blank">sharps disposal</a>.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-2-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 5: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis, is subcutaneous methotrexate more effective and/or safer than oral methotrexate?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1ZxJsFSDulqFHSAwQA2an2y39kh8lbF69/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-2-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Dr Samuel Whittle (Chair)</span>
<span class="panel-member">Prof Rachelle Buchbinder</span>
<span class="panel-member">Catherine Booth</span>
<span class="panel-member">Dr Helen Cooley</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Dr Grainne Murray</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Emily Sheridan</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Sarah Wilson</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">16 February 2023</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Subcutaneous%20methotrexate%20versus%20oral%20methotrexate%20for%20children%20and%20adolescents%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240270" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-3">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Uveitis</div>
                    <h2 class="modal-title">Biologic and targeted synthetic disease modifying anti-rheumatic drugs for JIA-associated uveitis with inadequate response to methotrexate</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-3', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-3', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-3', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-3', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-3', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-3-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with JIA-associated uveitis who have not responded to methotrexate, b/tsDMARDs should be considered. Adalimumab is recommended over other b/tsDMARDs. Etanercept is not recommended.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel considered evidence from RCTs that included patients with JIA-associated uveitis that has not adequately responded to methotrexate, treated with b/tdDMARDs.</p>
<p>Conclusions were limited by low participant numbers, relatively short follow up periods, heterogeneity with regard to outcome measures and a limited selection of bDMARDs assessed. The panel spent some time discussing outcome measures. Ocular damage (new structural ocular comorbidities or change in visual acuity) was highlighted as perhaps the most important long term outcome but one that is very difficult to assess in a randomised control trial environment. Two outcomes assessing ocular damage were deemed as being of very low certainty while the other included outcome measures were assessed as low certainty.</p>
<p>The panel agreed that not all bDMARDs and tsDMARDs are equal. All of the data considered by the panel were from patients treated with TNF-É‘ inhibitors. The etanercept trial, albeit limited to 12 participants, did not show any apparent beneficial treatment effect while the two adalimumab trials suggested a positive treatment response. These findings are supported by observational studies and there are also physiological reasons to explain this discrepancy.</p>
<p>While medications with other mechanisms of action (such as interleukin-6 inhibitors) are also used for the treatment of refractory JIA associated uveitis, the panel did not feel confident in extrapolating the findings from this review to non-TNF-É‘ bDMARDs or tsDMARDs.</p>
<p>The panel was strongly of the view that the benefits of adalimumab treatment were easily balanced by the burden of an injectable immunosuppressant medication, but that the decision to use it would be influenced by individual circumstances, preferences and values, and that a continuous, open and informed shared decision-making process should underpin any such decision. The panel considered the significant cost of adalimumab but still favoured it as a cost effective option given the risk of permanent ocular damage and lack of more cost effective, evidence based alternative treatments. The panel highlighted the importance of equitable access to high quality care including such treatments.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-3-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>Considering the overall benefits and harms (as summarised below), the panel concluded that there is a small to substantial benefit in recommending b/tsDMARDs in this population. Based on data from three randomised control trials (RCTs) in children and young people with JIA-associated uveitis who have not adequately responded to methotrexate, the use of b/tsDMARDs <sup><a href="https://doi.org/10.1136/annrheumdis-2017-212089" target="_blank" title="Quartier et al.">1</a></sup><sup><a href="https://doi.org/10.1056/NEJMoa1614160" target="_blank" title="Ramanan et al.">2</a></sup><sup><a href="https://doi.org/10.1002/art.20904" target="_blank" title="Smith et al.">3</a></sup>:</p>
<ul>
<li>may increase the likelihood of achieving treatment response</li>
<li>may decrease the likelihood of a uveitis flare or treatment failure</li>
<li>may increase the likelihood of weaning topical steroid drops to two or less per day</li>
<li>may have little or no effect on the number of eyes with improvement in anterior chamber (AC) cell count</li>
<li>may have little or no effect on the number of serious adverse events</li>
</ul>
<p>It is uncertain whether b/tsDMARDs have an effect on the development of new structural ocular comorbidities or visual acuity to to very low certainty of evidence.</p>
<p>Data on patient global assessment of disease activity and childhood health assessment questionnaire (CHAQ) were not able to be extracted from the available trials.</p>
<p>While the participant numbers in the included trials is limited (n=133), the overall results are consistent with observational trials. Etanercept and adalimumab are both tumour necrosis factor alpha (TNF-É‘) inhibitors but achieve this through different mechanisms and therefore have slightly different properties from one another <sup><a href="https://doi.org/10.1016/j.ophtha.2016.08.025" target="_blank" title="Cordero-Coma et al.">32</a></sup><sup><a href="https://doi.org/10.1002/ibd.20225" target="_blank" title="Nesbitt et al.">33</a></sup><sup><a href="https://doi.org/10.1186/s12348-020-00202-6" target="_blank" title="Nicolela et al. (2020)">34</a></sup><sup><a href="https://doi.org/10.1016/j.semarthrit.2005.01.009" target="_blank" title="Wallis et al.">35</a></sup>. TNF-É‘ inhibitors, also known as anti-TNF-É‘ medications, can broadly be described as either monoclonal antibodies (adalimumab, infliximab, golimumab, certolizumab) or fusion proteins (etanercept). In keeping with the findings from this review, data from JIA-associated uveitis registries and case series suggest that anti-TNF-É‘ monoclonal antibodies have superior treatment effect on uveitis when compared to fusion proteins <sup><a href="https://doi.org/10.1136/ard.2006.058248" target="_blank" title="Tynjala et al.">29</a></sup><sup><a href="https://doi.org/10.1136/annrheumdis-annrheumdis-2014-206747" target="_blank" title="Klotsche et al.">14</a></sup><sup><a href="https://doi.org/10.1002/art.22918" target="_blank" title="Lim et al.">16</a></sup>. Similar findings have been noted among adults with uveitis <sup><a href="https://doi.org/10.1016/j.semarthrit.2011.05.005" target="_blank" title="Wendling et al.">30</a></sup>. For these reasons, etanercept is not generally recommended for the treatment of JIA-associated uveitis <sup><a href="https://doi.org/10.1002/acr.23610" target="_blank" title="Angeles-Han et al.">5</a></sup><sup><a href="https://doi.org/10.1002/art.40885" target="_blank" title="Angeles-Han et al. (2019)">6</a></sup><sup><a href="https://doi.org/10.1136/annrheumdis-2018-213131" target="_blank" title="Constantin et al.">9</a></sup><sup><a href="https://doi.org/10.1111/ceo.13856" target="_blank" title="Smith et al.">25</a></sup>.</p>
<p>Cohort studies looking specifically at anti-TNF-É‘ monoclonal antibodies suggest that a significant number of patients with JIA-associated uveitis will respond favourably <sup><a href="https://doi.org/10.1136/bjo.2006.103721" target="_blank" title="Biester et al.">7</a></sup><sup><a href="https://doi.org/10.2147/OPTH.S23646" target="_blank" title="Kotaniemi et al.">15</a></sup><sup><a href="https://doi.org/10.1093/rheumatology/kem356" target="_blank" title="Tynjala et al.">28</a></sup><sup><a href="https://doi.org/10.3899/jrheum.120583" target="_blank" title="Zannin et al.">31</a></sup> and their use is supported in contemporary guidelines <sup><a href="https://doi.org/10.1002/acr.23610" target="_blank" title="Angeles-Han et al.">5</a></sup><sup><a href="https://doi.org/10.1002/art.40885" target="_blank" title="Angeles-Han et al. (2019)">6</a></sup><sup><a href="https://doi.org/10.1136/annrheumdis-2018-213131" target="_blank" title="Constantin et al.">9</a></sup><sup><a href="https://doi.org/10.1111/ceo.13856" target="_blank" title="Smith et al.">25</a></sup>.</p>
<p>RCTs are typically not powered to estimate differences in adverse events and may not have long enough follow-up periods to detect important long-term harms. The included trials were not able to detect a significant difference in the rate of ocular damage (measured by new structural ocular comorbidities or change in visual acuity) or serious adverse events. All three trials had pre-defined safety measures to censor patients and withdraw them from the trial in the event of a uveitis flare. After withdrawing from the trial, patients could be managed as per the treating team and were eligible to commence the investigational drug. Therefore, patients were unlikely to be exposed to prolonged periods of active inflammation and subsequent damage. This practice reflects the real world practice of treat to target strategies <sup><a href="https://doi.org/10.1136/annrheumdis-2018-213030" target="_blank" title="Ravelli et al.">21</a></sup>. Observational trials are perhaps better at assessing for these long term complications of disease and support a positive treatment effect for bDMARDs <sup><a href="https://doi.org/10.1186/s12969-018-0266-5" target="_blank" title="Cann et al.">8</a></sup><sup><a href="https://doi.org/10.1007/s10792-021-02043-1" target="_blank" title="Del et al.">36</a></sup>.</p>
<p>The side-effect profile of etanercept and adalimumab is well established through trials in other paediatric populations and post-marketing surveillance studies <sup><a href="https://doi.org/10.1002/acr2.11091" target="_blank" title="Klein et al.">13</a></sup>. The number of serious adverse events among the RCTs included in this review were low and they did not reveal any new concerning safety signals.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>There was low certainty evidence for likelihood of achieving treatment response, likelihood of a uveitis flare / treatment failure, likelihood of weaning topical steroid drops to two or less per day, number of eyes with improvement in AC cell count and number of serious adverse events. There was very low certainty evidence for the development of new structural ocular comorbidities and visual acuity. This uncertainty was largely due to indirectness (inclusion of only two types of bDMARDs, inclusion of patients with mild disease, short follow up period) and imprecision (low number of trial participants).</p>
<p>It must be noted that the available RCTs are limited to only two bDMARDs (2 adalimumab RCTs, 1 etanercept RCT). Contemporary guidelines make reference to other bDMARDs for the treatment of JIA associated uveitis including other TNF-É‘ inhibitors (infliximab, golimumab, certolizumab), interleukin-6 inhibitors (tocilizumab), T-cell costimulatory signal inhibitors (abatacept) and B-cell inhibitors (rituximab) <sup><a href="https://doi.org/10.1002/acr.23610" target="_blank" title="Angeles-Han et al.">5</a></sup><sup><a href="https://doi.org/10.1002/art.40885" target="_blank" title="Angeles-Han et al. (2019)">6</a></sup><sup><a href="https://doi.org/10.1136/annrheumdis-2018-213131" target="_blank" title="Constantin et al.">9</a></sup>. Given this review was limited to only two medications, we are unsure whether these findings can be extrapolated to other bDMARDs or to tsDMARDs.</p>
<p>There are two ongoing trials (1 baricitinib, 1 adalimumab) with anticipated completion dates in 2022 and 2024 <sup><a href="https://doi.org/10.1186/s13063-020-04796-z" target="_blank" title="Acharya et al.">4</a></sup><sup><a href="https://doi.org/10.1186/s13063-021-05651-5" target="_blank" title="Ramanan et al.">20</a></sup>. The results of these trials may impact the findings from this review.</p>
<p>The panel generally agreed with the plain language summaries although concerns were raised about the certainty of evidence. It was noted that some participants in one study (n=31) had very mild disease at baseline <sup><a href="https://doi.org/10.1136/annrheumdis-2017-212089" target="_blank" title="Quartier et al.">1</a></sup>. The major concern was that this could limit the applicability of this finding and potentially underestimate the treatment effect (particularly with regard to the number of affected eyes with AC cell count improvement given that this was the only trial included for this outcome).</p>
<p>It was also noted that the timeframe for follow up was relatively short and that RCTs are generally poorly set up to detect ocular damage (including new structural ocular comorbidities or change in visual acuity). While these are very important outcomes, it was determined that the certainty of evidence for these outcomes should be downgraded to very low.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">No substantial variability expected</span></div><div class="etd-domain-text"><p>A recent qualitative thematic analysis on patients with JIA-associated uveitis provides some insight into perspectives on the disease impact. Patients highlighted impacts of treatment (emotional response to treatment, medication side-effects, need for painful injections) and impacts of the disease (difficulties with seeing, risk of blindness, need for surgery) as significantly affecting their quality of life and emotional well-being <sup><a href="https://doi.org/10.1186/s12969-017-0189-6" target="_blank" title="Sen et al.">23</a></sup>.</p>
<p>The panel agreed that the impacts of disease and treatments are important to consider, however most consumers would choose treatment with b/tsDMARDs.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>b/tsDMARDs are a major cost to the Australian health care system. At the time of publication, the Pharmaceutical Benefits Scheme (PBS) listed price (including the approved ex-manufacturer price and all relevant dispensing fees and mark-ups) of adalimumab is $11,511.50 AUD per patient per year.</p>
<p>An analysis on cost effectiveness of one of the RCTs included in this review concluded that adalimumab is not cost effective when compared with methotrexate alone in the United Kingdom setting despite showing clinical efficacy <sup><a href="https://doi.org/10.1056/NEJMoa1614160" target="_blank" title="Ramanan et al.">2</a></sup><sup><a href="https://doi.org/10.1016/j.ophtha.2018.09.043" target="_blank" title="Hughes et al.">12</a></sup>. It must be noted that this analysis only considered short term health care expenditure and did not consider the longer term medical, societal or economic effects of treatment. The trial design, where participants were censored on flaring and able to access the investigational medication at that point, probably limited the ability to detect meaningful short term differences in visual acuity and structural ocular complications.</p>
<p>The costs to society of the sequelae of under-treated uveitis must not be underestimated. Observational studies of patients with non-infectious uveitis (particularly JIA-associated uveitis) in the era of bDMARDs shows improved outcomes when compared to historical comparison groups. Rates of visual impairment and other ocular complications appear to be considerably lower <sup><a href="https://doi.org/10.1186/s12969-018-0266-5" target="_blank" title="Cann et al.">8</a></sup>.</p>
<p>While the high treatment cost was considered by the panel, it was still felt that the findings of this review support the use of b/tsDMARDs given the implications of not using them. The permanent nature of ocular damage was highlighted. It was additionally noted that generic forms of these medications (â€˜biosimilarsâ€™ in the case of bDMARDs) are expected to be available in the near future and are likely to decrease the cost. Given that bDMARDs and tsDMARDs are often currently funded through industry funded compassionate access programs, there is no direct cost to the healthcare system at present. Regardless, a majority of the panel agreed that the cost of bDMARDs/tsDMARDs favours a recommendation for their use.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Equity has been considered with the PROGRESS framework (place of residence, race/ ethnicity/culture/language, occupation, gender/ sex, religion, education, socioeconomic status, and social capital) considered <sup><a href="https://doi.org/10.1016/j.jclinepi.2013.08.005" target="_blank" title="O'Neill et al.">18</a></sup>.</p>
<p>Financial constraints, the absence of specialists to supervise the use of drugs in clinical practice and drug unavailability have all been identified as major barriers to the use of b/tsDMARDs in Australasia <sup><a href="https://doi.org/10.1186/s12969-021-00498-1" target="_blank" title="Tangcheewinsirikul et al.">26</a></sup>.</p>
<p>The provision of tertiary paediatric rheumatology care in Australia is relatively constrained to major cities <sup><a href="https://doi.org/10.1111/1756-185X.12802" target="_blank" title="Cox et al.">10</a></sup>. Given the complexity and expense of b/tsDMARDs, it is unlikely that they are accessible without input from a metropolitan treating unit. Patients with low health literacy and self advocacy may also have limited access to these therapies.</p>
<p>The panel noted that this question pertains to patients already on methotrexate, meaning that they are highly likely to already be linked in with a tertiary paediatric rheumatology and ophthalmology service, decreasing the concerns about inequity. There was an equal number of panelists voting that b/tsDMARDs probably increase or probably have no impact on inequality.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>bDMARDs are given parenterally (by either subcutaneous or intravenous injection), while tsDMARDs are generally orally administered. Both add to the overall treatment burden experienced by patients with JIA-associated uveitis.</p>
<p>Injections are consistently highlighted as a drawback by children and young people with JIA on biologic medications however many patients are able to rationalise this treatment if it leads to improved disease control or reduction in overall treatment related side-effects <sup><a href="https://doi.org/10.1186/s12969-016-0083-7" target="_blank" title="Livermore et al.">17</a></sup>. These concerns may also be partially offset by concerns about possible complications of untreated disease and implications for schooling and other activities <sup><a href="https://doi.org/10.1186/s12969-017-0189-6" target="_blank" title="Sen et al.">23</a></sup>.</p>
<p>There is little evidence regarding the acceptability of b/tsDMARDs for the treatment of JIA-associated uveitis to clinicians, policymakers or other stakeholders, although the panel felt that use of these treatments in a shared decision-making framework would likely be acceptable to all stakeholders. The panel additionally noted that some modern formulations of subcutaneous bDMARDs without irritant preservatives (such as citrate) may partially alleviate concerns about painful injections. Most panellists agreed that b/tsDMARD are acceptable to all stakeholders.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There are no bDMARDs or tsDMARDs currently listed on the Pharmaceutical Benefits Scheme (PBS) to provide subsidised access to these treatments for the indication of JIA-associated uveitis in Australia. Access is dependent on compassionate access programs through pharmaceutical companies or hospital based therapeutic groups at present. It was noted by the panel that similar healthcare systems, including England and New Zealand, support programs that provide government funded access to bDMARDs including adalimumab for JIA-associated uveitis when certain clinical criteria are met.</p>
<p>The majority of panel members felt that it is probably feasible to recommend this intervention.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-3-practical">
                    <div class="content-section">
                        <ul>
<li>When considering b/tsDMARD for children and young people with JIA-associated uveitis who have not responded to methotrexate:
    <ul>
    <li>Adalimumab is recommended over other b/tsDMARDs</li>
    <li>Anti-TNF-É‘ fusion proteins (etanercept) should not be used</li>
    <li>Other anti-TNF-É‘ monoclonal antibodies (including infliximab), non-TNF-É‘ inhibitor bDMARDs and tsDMARDs can be considered although randomised evidence supporting efficacy or safety is lacking</li>
    </ul>
</li>
<li>Any decision regarding the use of b/tsDMARDs should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances (including comorbidities and concomitant medications).</li>
<li>b/tsDMARD treatment should be performed under the supervision of paediatric rheumatology and ophthalmology specialists with expertise in JIA-associated uveitis. Regular review is required to determine treatment response and medication tolerability.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-3-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 1: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with JIA-associated uveitis who have not responded to methotrexate, are b/tsDMARDs safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1boLgDnYJI2MjdJmC_2wYicRAnUUdgjaS/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-3-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Prof Rachelle Buchbinder (Chair)</span>
<span class="panel-member chair">Dr Sue Brennan (Facilitator)</span>
<span class="panel-member">David Pho</span>
<span class="panel-member">Emily Sheridan</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Dr Grainne Murray</span>
<span class="panel-member">Dr Jessica McGrath</span>
<span class="panel-member">Dr Joachim Tan</span>
<span class="panel-member">Dr Phillipa Sharwood</span>
<span class="panel-member">Dr Priscilla Campbell-Stokes</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Dr Samuel Whittle</span>
<span class="panel-member">Sarah Wilson</span>
<span class="panel-member">Dr Victoria Heaton</span>
<span class="panel-member">Dr William Renton</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">14 October 2021</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Choice%20of%20first-line%20advanced%20therapy%20for%20chronic%20anterior%20uveitis%20in%20children%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240271" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-4">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Conventional synthetic DMARD (csDMARD) dose reduction or discontinuation for juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-4', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-4', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-4', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-4', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-4', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-4-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with juvenile idiopathic arthritis who have experienced a sustained period of low or absent disease activity, and in whom the current or potential adverse effects of treatment outweigh the potential risk and impact of disease flare, consider a trial of dose reduction or discontinuation of csDMARDs.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel reviewed the scant evidence regarding the benefits and harms of dose reduction or discontinuation of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in children and young people with JIA. There are no randomised controlled trials (RCTs) that directly address this question. There has been one RCT that compared two strategies for methotrexate discontinuation, which found no difference in flare rates between people with JIA in clinically inactive disease who continued methotrexate for a further six months versus 12 months <sup><a href="https://doi.org/10.1001/jama.2010.375" target="_blank" title="Foell et al.">111</a></sup>. The panel noted that there was a relatively high rate of flare (approximately 20 percent annually) during the phase of continued methotrexate therapy (i.e., prior to discontinuation of treatment). In this trial, inactive disease was defined by the Wallace criteria, which do not include any patient-reported outcomes.</p>
<p>The panel also noted findings from two prospective <sup><a href="https://pubmed.ncbi.nlm.nih.gov/35633573/" target="_blank" title="Azevedo et al.">151</a></sup><sup><a href="https://doi.org/10.1136/annrheumdis-2017-211968" target="_blank" title="Klotsche et al.">152</a></sup> and three retrospective <sup><a href="https://doi.org/10.1542/PEDS.100.6.994" target="_blank" title="Gottlieb et al. (1997)">149</a></sup><sup><a href="https://pubmed.ncbi.nlm.nih.gov/7473486/" target="_blank" title="Ravelli et al.">150</a></sup><sup><a href="https://doi.org/10.46497/ArchRheumatol.2023.10035" target="_blank" title="Ä°ÅŸgÃ¼der et al.">153</a></sup> observational studies. All of these studies included children and young people with JIA who discontinued methotrexate; flare rates ranged from 33% to 58%. No reliable predictors of flare were identified, although a longer period of clinically inactive disease was associated with a reduced risk of flare in one cohort <sup><a href="https://doi.org/10.1136/annrheumdis-2017-211968" target="_blank" title="Klotsche et al.">152</a></sup>. There is also limited evidence regarding the rate of recapture of adequate disease control upon recommencement of csDMARDs in those who flare. Registry data suggest that approximately two-thirds of children achieve a state of inactive disease within 12 months of recommencing DMARDs (including csDMARDs and bDMARDs) <sup><a href="https://doi.org/10.1002/acr.24994" target="_blank" title="Ringold et al.">147</a></sup>.</p>
<p>Despite the lack of evidence, the panel considered it important to develop a recommendation on this topic. Tapering and discontinuation of DMARDs in patients with JIA who have responded well to treatment is the highest priority guideline question among Australian and New Zealand paediatric rheumatologists and healthcare professionals <sup><a href="https://doi.org/10.1186/s12969-022-00710-w" target="_blank" title="Tiller et al.">86</a></sup>, however there are currently no international guideline recommendations on this topic.</p>
<p>Panellists reported that in their clinical and lived experience, DMARD dose reduction and discontinuation is a question of interest to children and young people with JIA, their families, and their healthcare team, particularly in regard to methotrexate, and that there is likely to be variation in current clinical practice.</p>
<p>While there is likely to be relative uniformity in the desire to achieve and maintain a state of clinical remission with the lowest possible exposure to medications, the balance between treatment efficacy and harm is contingent on multiple individual factors, including the subtype of JIA, prior clinical features and severity (including prior joint damage), a history of extra-articular disease manifestations (particularly uveitis), the duration of clinically inactive disease, age, responsiveness of the disease to treatment, comorbidity, and individual life circumstances, preferences, values and treatment goals.</p>
<p>Given the lack of evidence from RCTs and the relatively high rate of flare reported in observational studies, the panel acknowledged that continuation of csDMARDs may be the preferred choice for many children and young people with JIA, particularly those who have tolerated treatment well. However, it was the view of the panel that a conditional recommendation in favour of a trial of treatment withdrawal may permit exploration of the possibility of remission off medication, which remains a realistic possibility for a substantial proportion of children and young people with JIA who have achieved sustained disease control with DMARDs. As a conditional recommendation, it is highly dependent on individual factors and preferences.</p>
<p>Although it remains unclear whether a prolonged period of inactive disease increases the probability of successful withdrawal of csDMARDs, the panel noted that it is currently common practice among Australian and New Zealand paediatric rheumatologists to favour a period of quiescent disease of at least a year before considering reduction in therapy.</p>
<p>The majority of the existing observational data on csDMARD dose reduction relate to methotrexate, and this was the primary focus of the panel discussion, however the issues considered and, therefore, the recommendation itself, may be applied similarly to other csDMARDs.</p>
<p>The current recommendation applies to children and young people with JIA who have achieved good disease control with csDMARDs alone; future living recommendations in this guideline will address the question of adjustment of the DMARD regimen in people who have achieved good disease control with a combination of csDMARDs and b/tsDMARDs, and the role of csDMARDs in preventing immunogenicity in people using concurrent bDMARDs.</p>
<p>The importance of this question and the current lack of evidence highlights the importance and urgency of RCTs addressing this topic. This living recommendation will continue to be updated as soon as relevant new information becomes available.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-4-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p><strong>csDMARD Dose Reduction</strong></p>
<p>We did not identify any systematic reviews or randomised controlled trials that addressed this question.</p>
<p><strong>csDMARD Discontinuation</strong></p>
<p>We identified one systematic review that summarised current evidence about medication withdrawal for children and young people with JIA in remission. The review included one randomised controlled trial <sup><a href="https://doi.org/10.1001/jama.2010.375" target="_blank" title="Foell et al.">111</a></sup> that examined two different csDMARD (methotrexate) discontinuation strategies, however there was no continuation arm, so the trial did not directly address our question. Participants in this trial were receiving methotrexate for JIA and had achieved a state of clinically inactive disease (CID). They were randomised to continue methotrexate for either a further six months or 12 months before abrupt discontinuation. While there was no difference between groups in flare rates with the 24 months following discontinuation of methotrexate, separate data were not provided for the period of time (6-12 months) when participants in one arm stopped methotrexate while participants in the other arm remained on methotrexate.</p>
<p>We are therefore uncertain of the benefits and harms of dose reduction or discontinuation of csDMARDs in children and young people with JIA with clinically inactive disease on disease activity and remission rates, flare and safety compared with continuation of csDMARDs.</p>
<p>The panel noted the lack of RCT evidence that addresses this question. The panel discussed the existing observational evidence, including data from two national registries (Germany <sup><a href="https://doi.org/10.1136/annrheumdis-2017-211968" target="_blank" title="Klotsche et al.">156</a></sup> and Portugal <sup><a href="https://pubmed.ncbi.nlm.nih.gov/35633573/" target="_blank" title="Azevedo et al.">157</a></sup>). While these data suggest a flare rate of around 50% in children and young people with JIA who discontinue csDMARDs, a relatively high flare rate in those who continue csDMARDs was also noted. There is currently insufficient evidence to determine the relative benefits and harms of csDMARD dose reduction or discontinuation strategies in this population.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very low</span></div><div class="etd-domain-text"><p>No RCTs were identified that directly address this question.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>In general, outcomes of importance to children and young people with JIA include reduction in pain, reduced frequency of disease flares, improved quality of life, and the ability to engage in normal social, educational and sporting activities <sup><a href="https://doi.org/10.1186/s12969-023-00906-8" target="_blank" title="McErlane et al.">144</a></sup><sup><a href="https://doi.org/10.3899/jrheum.131536" target="_blank" title="Guzman et al.">145</a></sup><sup><a href="https://doi.org/10.11124/JBIES-21-00139" target="_blank" title="Min et al.">146</a></sup>. While medication adverse effects, treatment burden, active joint disease, pain, and quality of life are afforded a high priority by young people living with JIA, their parents, and paediatric rheumatologists, the relative importance of these features varies within and between these groups <sup><a href="https://doi.org/10.3899/jrheum.131536" target="_blank" title="Guzman et al.">145</a></sup>.</p>
<p>A qualitative study in the US of young people with JIA and caregivers investigated the factors influencing decisions about stopping medications when JIA is inactive <sup><a href="https://doi.org/10.1002/acr.24129" target="_blank" title="Horton et al.">148</a></sup>. Participants varied in their weighting of the competing risks of disease activity and treatment, influenced by a variety of factors including their lived experience of the disease and its treatments. Treatment withdrawal decisions tended to be influenced by the individual&#x27;s perception of either disease activity or medications as posing the greater health risk.</p>
<p>A discrete choice experiment performed among UK and US adolescents with JIA and caregivers for children with JIA found that, overall, both young people with JIA and their caregivers value symptom control and a reduced risk of arthritis flare most highly; avoidance of adverse effects, including nausea, vomiting, and headache was also rated as important <sup><a href="https://doi.org/10.1186/s12969-023-00906-8" target="_blank" title="McErlane et al.">144</a></sup>. However, there was considerable heterogeneity in the weighting of treatment trade-offs. Adolescents with JIA were more likely to attribute importance to avoidance of adverse effects than caregivers, who tended to attribute greater importance to treatment efficacy. Participants were generally indifferent to the mode of treatment administration.</p>
<p>Based on these findings, there is likely to be variability between individuals in their weighting of the primary trade-off for those contemplating dose reduction, between an increased risk of disease flare and a lower risk of medication adverse effects.</p>
<p>The panel noted the importance of individual values and preferences in making decisions about csDMARD dose reduction or discontinuation, and discussed the many additional factors that are likely to be salient in such a decision, including age, prior experience of disease flares, type of JIA, clinical features of the disease (particularly uveitis), medication adverse effects, life circumstances (e.g. school stage), and the prior responsiveness of the disease to DMARD therapy (e.g. time to achieve remission or low disease activity).</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>We did not identify any direct data on the resource implications of dose reduction or discontinuation of csDMARDs in children and young people with JIA. csDMARDs are generally a low-cost intervention, and therefore the direct cost impact of dose reduction or discontinuation at both the individual and system level is likely to be relatively minor. There may be additional direct or indirect costs associated with disease flare, including additional healthcare, reduced participation in school, sport and social activities, and an increased burden on carers.</p>
<p>The importance of any out-of-pocket cost difference may vary between individual patients, particularly in light of the current relatively high cost-of-living in Australia. There is evidence that out-of-pocket healthcare costs may act as a barrier to accessing treatment for some people - as many as 25% of Australians living with adult forms of arthritis report skipping healthcare treatment due to cost <sup><a href="https://doi.org/10.1071/PY16005" target="_blank" title="Callander et al.">158</a></sup>.</p>
<p>While there are no data that specifically estimate the effect of csDMARD dose reduction or discontinuation on the environment, it is plausible that reduced prescription drug use may lower any negative impact on the environment attributable to manufacturing, packaging and transport. The magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
<p>The panel considered that the resource implications of this recommendation are likely to be relatively low, but that there might be variable cost implications for individuals regardless of their decision to continue or discontinue csDMARDs. It was noted by a panellist that many young people with JIA express concern about the environmental impact of their health care. In light of these considerations and the lack of existing evidence, the panel chose a rating of â€œimportant issues, or potential issues not investigatedâ€.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Many factors influence individual patient&#x27;s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect csDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p>
<p>The panel considered that there were likely to be relatively few differential health equity consequences of the different dose reduction strategies, however there remained potential for such differences to exist. The panel acknowledged that inequity is an important concern but considered that DMARD dose reduction is unlikely to have a substantial differential impact on existing health inequity.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>A survey of North American paediatric rheumatologists found that there was considerable variability in decision-making regarding withdrawal of DMARDs for children with clinically inactive non-systemic JIA <sup><a href="https://doi.org/10.3899/jrheum.161078" target="_blank" title="Horton et al.">154</a></sup>. There were differences in the duration of inactive disease before stopping DMARDs, and whether to reduce, taper or stop medications. The majority of respondents preferred to stop methotrexate first in children and young people with clinically inactive JIA who were receiving combination DMARD therapy that included methotrexate.</p>
<p>While a trial of csDMARD dose reduction or discontinuation is likely to be acceptable to many children and young people with JIA and their families in the context of clinically inactive disease, there is likely to be variability in the degree of acceptability within and between stakeholder groups.</p>
<p>The panel noted that although a conditional recommendation that incorporates consideration of individual values and preferences is likely to be relatively acceptable to all stakeholders, it was likely that the degree of acceptability may vary.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>While csDMARD dose reduction or discontinuation is likely to be feasible for many individuals with JIA, there are potential barriers to implementation in some settings, particularly where access to care and support may be limited during the period of dose modification.</p>
<p>The panel considered that decisions regarding csDMARD continuation are already part of usual practice, and therefore the recommendation is likely to be broadly feasible. However it was also noted that the current lack of evidence to support the recommendation and the current variation in practice may represent a barrier to broad or consistent implementation of this recommendation.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-4-practical">
                    <div class="content-section">
                        <ul>
<li>A treat-to-target approach is recommended for all patients with juvenile idiopathic arthritis (JIA), including during dose reduction.</li>
<li>All decisions regarding the DMARD regimen in children and young people with JIA should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances.</li>
<li>A decision regarding dose reduction or discontinuation of csDMARDs should take into account a number of potentially-relevant factors, such as:
    <ul>
    <li>Individual values and preferences</li>
    <li>Type of JIA and clinical features in the individual patient</li>
    <li>Prior disease activity and impact (particularly the presence of joint damage)</li>
    <li>Adverse effects of csDMARDs</li>
    <li>Age</li>
    <li>Developmental and life circumstances</li>
    <li>Comorbidity</li>
    <li>Concomitant medications</li>
    </ul>
</li>
<li>A history of uveitis may indicate that additional caution is required when considering discontinuation of DMARDs.
    <ul>
    <li>An Australian and New Zealand JIA-Uveitis Working Group recommended in 2020 that cessation of systemic immunosuppressive drugs may be considered when the uveitis has been inactive for 24 months <sup><a href="https://doi.org/10.1111/ceo.13856" target="_blank" title="Smith et al.">25</a></sup>.</li>
    <li>Close monitoring for recurrence of uveitis should be undertaken after csDMARDs are dose reduced or discontinued.</li>
    </ul>
</li>
<li>Given the absence of evidence, the decision between stepwise dose reduction and abrupt discontinuation of csDMARDs may be informed by individual factors, including current medication adverse effects, prior disease activity, life circumstances, and the values and preferences of the patient and their family.</li>
<li>While this recommendation is based on limited data, a stable low disease activity state for at least 12 months is likely to be the minimum time frame for consideration of csDMARD dose reduction, and maintenance of the treatment target for longer (e.g. 18 to 24 months) may represent optimal preconditions for a trial of dose reduction or discontinuation.</li>
<li>Following csDMARD dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure.</li>
<li>Families should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a clear mechanism for contacting the treating team between visits if necessary.</li>
<li>In the event of loss of disease control (e.g., persistent increase in composite disease activity measure or new symptoms that are unacceptable to the patient), we recommend reintroduction of the previous effective DMARD regimen.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-4-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 6: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis who have achieved sustained remission or low disease activity, is dose reduction or discontinuation of csDMARDs safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1f0iELJ8uEYvGOPPoz42rohGWxumgw4Q5/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-4-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Prof Rachelle Buchbinder (Chair)</span>
<span class="panel-member">Catherine Booth</span>
<span class="panel-member">Dr Priscilla Campbell-Stokes</span>
<span class="panel-member">Cass Gannon</span>
<span class="panel-member">Dr Mariya Hamid</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Jane Munro</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Tracy Rose</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Prof Lyndal Trevena</span>
<span class="panel-member">Dr Samuel Whittle</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">12 December 2024</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Dose%20reduction%20or%20discontinuation%20of%20csDMARDs%20for%20children%20and%20adolescents%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240273" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-5">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Dose Reduction</div>
                    <h2 class="modal-title">Biologic or targeted synthetic DMARD (b/tsDMARD) dose reduction or discontinuation for juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-5', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-5', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-5', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-5', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-5', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-5-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with juvenile idiopathic arthritis who have experienced a sustained period of inactive disease, and in whom the current or potential adverse effects of treatment outweigh the potential risk and impact of disease flare, consider a trial of dose reduction or discontinuation of b/tsDMARDs.  </p></div>
                    <div class="remark-box"><p>Additional caution may be warranted in those with a history of uveitis.</p></div>
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel reviewed the current evidence regarding dose reduction or discontinuation of b/tsDMARDs in children and young people with JIA. While evidence was available from thirteen RCTs of b/tsDMARD discontinuation, the majority of these trials were designed to demonstrate efficacy and, as such, exposure to b/tsDMARDs was relatively brief, and many of the participants had not achieved the prolonged clinically-inactive disease that would typically prompt a discussion of treatment reduction in clinical practice. Furthermore, there were no clinical trials of b/tsDMARD dose reduction in JIA. Therefore, the panel had little direct evidence regarding the relative benefits and harms of dose reduction or discontinuation in children and young people with JIA who have achieved excellent disease control with b/tsDMARDs, or on the predictors of successful dose reduction.</p>
<p>Further, while the current evidence base (including data from both RCTs and observational studies) indicates that withdrawal of therapy is likely to be associated with a risk of disease flare, the panel recognised that many young people with JIA (and their families) desire a life free from medications and may wish to explore a trial of dose reduction or discontinuation despite the risk of flare.</p>
<p>Indeed, while there are currently no international guideline recommendations on this topic in non-systemic JIA, tapering and discontinuation of DMARDs in patients with JIA who have responded well to treatment is the highest priority guideline question among Australian and New Zealand paediatric rheumatologists and healthcare professionals <sup><a href="https://doi.org/10.1186/s12969-022-00710-w" target="_blank" title="Tiller et al.">86</a></sup>. Panellists reported that in their clinical and lived experience, DMARD dose reduction and discontinuation is a question of interest to children and young people with JIA, their families, and their healthcare team, and that there is likely to be variation in current clinical practice. In light of this, the panel elected to develop a recommendation despite the paucity of evidence.</p>
<p>Given the uncertainty, and the risk of disease flare (particularly in the population of people with JIA who have required advanced therapies to achieve disease control), the panel acknowledged that continuation of b/tsDMARDs may be the preferred choice for many children and young people with JIA, especially those who have tolerated treatment well. However, it was the view of the panel that a conditional recommendation in favour of a trial of treatment withdrawal may permit exploration of the possibility of remission off medication, which remains a realistic possibility for a substantial proportion of children and young people with JIA who have achieved sustained disease control with DMARDs.</p>
<p>As a conditional recommendation, it is highly dependent on individual values, preferences, goals, experiences and context. The panel reiterated the importance of a shared decision based on consideration of all relevant factors, including the subtype of JIA, prior clinical features and severity (including prior joint damage and extra-articular disease manifestations, particularly uveitis), the duration of clinically inactive disease, age, responsiveness of the disease to treatment, comorbidity, and individual life circumstances.</p>
<p>The panel noted that a history of uveitis, in particular, is an important consideration due to the risk and potential impact of a flare, and highlighted the importance of close follow-up in this group. The panel discussed the results of the ADJUST trial <sup><a href="https://doi.org/10.1016/S0140-6736(24)02468-1" target="_blank" title="Acharya et al.">168</a></sup>, which showed an increased risk of articular and ocular flare in people with JIA-associated uveitis who discontinued adalimumab after at least one year of controlled disease, although all who flared recaptured disease control by the end of the study period.</p>
<p>The panel also noted that children and young people with systemic-onset JIA who have achieved a sustained remission with treatment may be more likely to successfully withdraw from therapy than those with non-systemic JIA, although the same caveats apply, including consideration of individual contextual factors, the need for explicit planning in a shared decision-making framework, close follow-up, and a clear plan for intervention in the case of disease flare.</p>
<p>This conditional recommendation, and the relevant individual considerations, is very similar to our <a href="#jia-rec-4" onclick="openModal('jia-rec-4'); return false;">recommendation on dose reduction or discontinuation of csDMARDs</a>. For the current recommendation, the panel considered that the risks or consequences of disease flare may be higher in the population of people with JIA who have required b/tsDMARDs, and therefore suggested a slightly more stringent description of the target disease state (â€œa sustained period of inactive diseaseâ€) to reflect the clinical impression that a prolonged period of inactive disease probably represents the optimal conditions under which to undertake a trial of treatment reduction.</p>
<p>This recommendation applies equally to children and young people with JIA who have achieved a state of inactive disease with b/tsDMARDs either alone or in combination with csDMARDs. It does not address which DMARD to discontinue first in those who are using a combination of csDMARDs and b/tsDMARDs. This will be the subject of a future recommendation.</p>
<p>The recommendation does not favour either dose reduction or discontinuation as the preferred method of dose adjustment. This decision is also highly conditional and depends on a number of considerations within the individual context. While gradual dose reduction may, in theory, reduce the risk of flare and permit exploration of the lowest effective dose, there are concerns that dose reduction may increase the risk of immunogenicity to the bDMARD and therefore risk loss of efficacy in the event of a disease flare <sup><a href="https://doi.org/10.1093/rheumatology/kez285" target="_blank" title="Verstegen et al.">177</a></sup><sup><a href="https://doi.org/10.3389/fimmu.2020.00312" target="_blank" title="Atiqi et al. (2020)">178</a></sup>. This may be a particularly important consideration in some settings, such as uveitis, in which there are few effective therapies.</p>
<p>The importance of this question and the current lack of evidence highlights the importance and urgency of RCTs that directly address this topic. This living recommendation will continue to be updated as soon as relevant new information becomes available.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-5-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p><strong>b/tsDMARD Dose Reduction</strong></p>
<p>We did not identify any systematic reviews or randomised controlled trials that addressed this question for children and young people with juvenile idiopathic arthritis (systemic or non-systemic).</p>
<p><strong>b/tsDMARD Discontinuation</strong></p>
<p><strong>Non-systemic JIA:</strong> Compared to continuation of treatment at the standard dose, discontinuation of b/tsDMARDs in children and young people with non-systemic juvenile idiopathic arthritis, with clinically inactive disease:</p>
<ul>
<li>May result in more people experiencing a flare of articular disease, more people experiencing a flare of ocular disease, and in fewer people remaining in a state of clinically inactive disease</li>
<li>We are uncertain whether discontinuation results in more serious adverse events or more withdrawals due to adverse events</li>
<li>No studies measured remission off medication</li>
</ul>
<p><strong>Systemic JIA (SoJIA):</strong> Compared to continuation of treatment at the standard dose, discontinuation of b/tsDMARDs in children and young people with systemic juvenile idiopathic arthritis with clinically inactive disease:</p>
<ul>
<li>May result in fewer people with clinically inactive disease and more people experiencing flare of articular disease</li>
<li>We are uncertain if discontinuation results in more people experiencing flare of systemic disease (very low event rates)</li>
<li>We are uncertain if discontinuation results in fewer people experiencing serious adverse events or withdrawing due to adverse events</li>
<li>No studies measured remission off medication</li>
</ul>
<p>The panel noted the absence of RCT evidence regarding b/tsDMARD dose reduction, and highlighted the relative indirectness of the existing trial evidence for b/tsDMARD discontinuation.</p>
<p>The panel considered that while the rate of flare following discontinuation of b/tsDMARDs is likely to be relatively high, a proportion of people with JIA may be able to successfully discontinue therapy. Given that there is likely to be variation between subtypes of JIA, between individuals within each subtype, and within the same individual over time, and that there are few reliable clinical or laboratory predictors of success, the panel concluded that there remains considerable uncertainty in the relative benefits and harms associated with b/tsDMARD dose reduction or discontinuation in children and young people with JIA.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>No trials addressed b/tsDMARD dose reduction.</p>
<p>In children and young people with <strong>non-systemic juvenile idiopathic arthritis</strong> who discontinued b/tsDMARDs:</p>
<ul>
<li>There was low certainty evidence that discontinuation may result in more flares of articular disease, and may result in fewer people with clinically inactive disease (downgraded twice for indirectness)</li>
<li>There was low certainty evidence that discontinuation may result in more flares of ocular disease (downgraded for indirectness and imprecision)</li>
<li>We are uncertain whether discontinuation results in more serious adverse events or more withdrawals due to adverse events (downgraded for imprecision and twice for indirectness)</li>
<li>No studies were identified that measured remission off medication.</li>
</ul>
<p>In children and young people with <strong>systemic juvenile idiopathic arthritis</strong> who discontinued b/tsDMARDs:</p>
<ul>
<li>There was low certainty evidence that discontinuation may result in fewer people with clinically inactive disease and in more people with flare of articular disease (downgraded for indirectness and for imprecision).</li>
<li>There was very low certainty evidence for the effects of discontinuation on flare of systemic disease, serious adverse events and withdrawals due to adverse events (downgraded for indirectness and for very few events).</li>
<li>No studies were identified that measured remission off medication.</li>
</ul>
<p>The panel discussed the existing RCT evidence at length, including the absence of RCT evidence regarding dose reduction. The panel noted that most of the evidence regarding b/tsDMARD discontinuation comes from withdrawal trials that were designed to demonstrate treatment efficacy rather than assess the benefits and harms of treatment reduction, and that therefore many of the participants had not achieved clinically inactive disease and had received b/tsDMARDs for a relatively brief period.</p>
<p>Given that this population does not reflect the population of interest in clinical practice (i.e., those who have achieved sustained inactive disease with b/tsDMARD therapy), and that there may be differences between subtypes of non-systemic JIA, the panel considered there to be very serious concerns about indirectness of the data, and voted to downgrade the certainty of the evidence twice for indirectness for all outcomes other than flares of ocular disease, for which an RCT that directly addressed this population provided most of the data. As a result, we have, at best, low certainty regarding the estimated impact of b/tsDMARD discontinuation on disease activity, and even lower certainty regarding the impact on DMARD safety or tolerability.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>In general, outcomes of importance to children and young people with JIA include reduction in pain, reduced frequency of disease flares, improved quality of life, and the ability to engage in normal social, educational and sporting activities <sup><a href="https://doi.org/10.1186/s12969-023-00906-8" target="_blank" title="McErlane et al.">144</a></sup><sup><a href="https://doi.org/10.3899/jrheum.131536" target="_blank" title="Guzman et al.">145</a></sup><sup><a href="https://doi.org/10.11124/JBIES-21-00139" target="_blank" title="Min et al.">146</a></sup>. While medication adverse effects, treatment burden, active joint disease, pain, and quality of life are afforded a high priority by young people living with JIA, their parents, and paediatric rheumatologists, the relative importance of these features varies within and between these groups <sup><a href="https://doi.org/10.3899/jrheum.131536" target="_blank" title="Guzman et al.">145</a></sup>.</p>
<p>A qualitative study in the US of young people with JIA and caregivers investigated the factors influencing decisions about stopping medications when JIA is inactive <sup><a href="https://doi.org/10.1002/acr.24129" target="_blank" title="Horton et al.">148</a></sup>. Participants varied in their weighting of the competing risks of disease activity and treatment, influenced by a variety of factors including their lived experience of the disease and its treatments. Treatment withdrawal decisions tended to be influenced by the individual&#x27;s perception of either disease activity or medications as posing the greater health risk.</p>
<p>A discrete choice experiment performed among UK and US adolescents with JIA and caregivers for children with JIA found that, overall, both young people with JIA and their caregivers value symptom control and a reduced risk of arthritis flare most highly; avoidance of adverse effects, including nausea, vomiting, and headache was also rated as important <sup><a href="https://doi.org/10.1186/s12969-023-00906-8" target="_blank" title="McErlane et al.">144</a></sup>. However, there was considerable heterogeneity in the weighting of treatment trade-offs. Participants with biologics experience tended to place more importance on improvement in symptom control, relative to other attributes. Adolescents with JIA were more likely to attribute importance to avoidance of adverse effects than caregivers, who tended to attribute greater importance to treatment efficacy. Participants were generally indifferent to the mode of treatment administration.</p>
<p>Based on these findings, there is likely to be variability between individuals in their weighting of the primary trade-off for those contemplating dose reduction, between an increased risk of disease flare and a lower risk of medication adverse effects.</p>
<p>The panel agreed that decisions regarding dose reduction or discontinuation of b/tsDMARDs are highly context-dependent, and that while many young people with JIA are likely to be interested in the possibility of discontinuation of medications over the long term, there is likely to be considerable variation in values and preferences between individuals and even within the same individual over time. There are numerous factors that contribute to this variability, including age, prior experience of disease flares, type of JIA, clinical features of the disease (particularly uveitis), medication adverse effects, life circumstances (e.g. school stage), and the prior responsiveness of the disease to DMARD therapy (e.g. time to achieve remission or low disease activity).</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>We did not identify any direct data on the cost-effectiveness of dose reduction or discontinuation of b/tsDMARDs in children and young people with JIA. b/tsDMARDs are generally considered to be expensive therapies and therefore strategies to reduce the total cumulative dose are likely to reduce costs for payers (governments and insurers) and may reduce out-of-pocket costs for patients. There are no publicly-available data regarding the actual comparative costs of different bDMARDs to the payer (i.e. the Federal Government) in Australia. There may be additional direct or indirect costs associated with disease flare, including additional healthcare, reduced participation in school, sport and social activities, and an increased burden on carers.</p>
<p>In a study in a European setting, medications accounted for 80% of total annual costs in people with JIA treated with TNFi; the mean annual cost fell by over 40% in the first year after TNFi discontinuation, but increased again slightly in the following year as bDMARDs were recommenced in those who flared <sup><a href="https://doi.org/10.1093/rheumatology/kead688" target="_blank" title="Florax et al.">179</a></sup>.</p>
<p>In the Australian context, the direct cost impact for individual patients is relatively small but this may differ in other settings. The importance of direct out-of-pocket cost implications of dose reduction versus continuation is likely to vary between individual patients. There is evidence that out-of-pocket healthcare costs may act as a barrier to accessing treatment for some people - as many as 25% of Australians living with adult forms of arthritis report skipping healthcare treatment due to cost <sup><a href="https://doi.org/10.1071/PY16005" target="_blank" title="Callander et al.">158</a></sup>.</p>
<p>A recent online survey conducted by the Juvenile Arthritis Foundation Australia (JAFA) estimated that total out of pocket annual costs related to JIA were AUD$4,292. The highest contributors to out of pocket costs were visits to healthcare professionals ($1,347) and transport and accommodation ($781). Almost half (48%) of respondents indicated they were in financial hardship over the last 12 months.</p>
<p>While there are no data that specifically estimate the effect of b/tsDMARD dose reduction or discontinuation on the environment, it is plausible that reduced prescription drug use may lower any negative impact on the environment attributable to manufacturing, packaging and transport. The magnitude of such an impact (if present) or other indirect effects is currently unknown.</p>
<p>The panel noted the uncertainty regarding the trade-off between lower medication costs and potential higher healthcare utilisation (and other costs) in the event of flare, at both the societal and individual level.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Many factors influence individual patient&#x27;s health opportunities and outcomes. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may affect b/tsDMARD dose reduction, including an impact on access to urgent specialist care or advice in the event of a flare in disease activity following DMARD dose adjustment.</p>
<p>The panel considered that the health equity implications of b/tsDMARD dose reduction or discontinuation are unlikely to be a major determinant of this recommendation, although there is uncertainty regarding the impact of potential differences in access to care in the event of a disease flare.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>A survey of North American paediatric rheumatologists found that there was considerable variability in decision-making regarding withdrawal of DMARDs for children with clinically inactive non-systemic JIA <sup><a href="https://doi.org/10.3899/jrheum.161078" target="_blank" title="Horton et al.">154</a></sup>. There were differences in the duration of inactive disease before stopping DMARDs, and whether to reduce, taper or stop medications. Another survey of paediatric rheumatologists indicated that the most important determinants in making this decision were how challenging it was to achieve remission, a history of established joint damage, and the amount of time spent in remission <sup><a href="https://doi.org/10.1007/s10067-023-06616-6" target="_blank" title="Currie et al.">180</a></sup>.</p>
<p>While a trial of b/tsDMARD dose reduction or discontinuation is likely to be acceptable to many children and young people with JIA and their families in the context of clinically inactive disease, there is likely to be variability in the degree of acceptability within and between stakeholder groups.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>While b/tsDMARD dose reduction or discontinuation is likely to be feasible for many individuals with JIA, there are potential barriers to implementation in some settings, particularly where access to care and support may be limited during the period of dose modification. Implementation of the recommendation may also be influenced by local prescribing rules or reimbursement conditions, although in general the current Australian reimbursement rules permit resumption of a previously-effective b/tsDMARD in the event of flare. While rheumatologists will typically offer a plan for urgent review in the event of a flare, there may be variation in the extent to which this is feasible.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-5-practical">
                    <div class="content-section">
                        <ul>
<li>A treat-to-target approach is recommended for all patients with juvenile idiopathic arthritis (JIA), including during dose reduction.</li>
<li>All decisions regarding the DMARD regimen in children and young people with JIA should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances.</li>
<li>A decision regarding dose reduction or discontinuation of b/tsDMARDs should take into account a number of potentially-relevant factors, such as:
    <ul>
    <li>Individual values and preferences</li>
    <li>Type of JIA and clinical features in the individual patient</li>
    <li>Prior disease activity and impact (particularly the presence of joint damage)</li>
    <li>Adverse effects of b/tsDMARDs</li>
    <li>Age</li>
    <li>Developmental and life circumstances</li>
    <li>Comorbidity</li>
    <li>Concomitant medications</li>
    </ul>
</li>
<li>A history of uveitis may indicate that additional caution is required when considering discontinuation of DMARDs.
    <ul>
    <li>An Australian and New Zealand JIA-Uveitis Working Group recommended in 2020 that cessation of systemic immunosuppressive drugs may be considered when the uveitis has been inactive for 24 months <sup><a href="https://doi.org/10.1111/ceo.13856" target="_blank" title="Smith et al.">25</a></sup>.</li>
    <li>Close monitoring for recurrence of uveitis should be undertaken after b/tsDMARDs are dose reduced or discontinued.</li>
    </ul>
</li>
<li>Given the lack of evidence, the decision between stepwise dose reduction and abrupt discontinuation of b/tsDMARDs may be informed by individual factors, including current medication adverse effects, prior disease activity, life circumstances, theoretical risk and impact of immunogenicity, and the values and preferences of the patient and their family.</li>
<li>While this recommendation is based on limited data, a stable low disease activity state for at least 12 months is likely to be the minimum time frame for consideration of b/tsDMARD dose reduction, and maintenance of the treatment target for longer (e.g. 18 to 24 months) may represent optimal preconditions for a trial of dose reduction or discontinuation.</li>
<li>Following b/tsDMARD dose reduction, clinical review should occur at least every 3 months and should include measurement of disease activity using a validated composite disease activity measure.</li>
<li>Families should be provided with a plan to follow if there is a symptomatic flare following dose reduction, including a clear mechanism for contacting the treating team between visits if necessary.</li>
<li>In the event of loss of disease control (e.g., persistent increase in composite disease activity measure or new symptoms that are unacceptable to the patient), we recommend reintroduction of the previous effective DMARD regimen.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-5-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 7: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis who have achieved sustained remission or inactive disease, is dose reduction or discontinuation of b/tsDMARDs safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1bQMl0VkPwO6xgQ7y5I4NNoOc2Jh1h8i8/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-5-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Prof Rachelle Buchbinder (Chair)</span>
<span class="panel-member">Catherine Booth</span>
<span class="panel-member">Dr Priscilla Campbell-Stokes</span>
<span class="panel-member">Cass Gannon</span>
<span class="panel-member">Dr Mariya Hamid</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Jane Munro</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Tracy Rose</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Prof Lyndal Trevena</span>
<span class="panel-member">Dr Samuel Whittle</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">1 October 2025</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Dose%20reduction%20or%20discontinuation%20of%20b/tsDMARDs%20for%20children%20and%20adolescents%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/241614" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-6">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Glucocorticoids</div>
                    <h2 class="modal-title">Short-term adjunctive induction glucocorticoids for non-systemic juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-6', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-6', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-6', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-6', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-6', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-6-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people starting a disease modifying anti-rheumatic drug for non-systemic juvenile idiopathic arthritis, we conditionally recommend the short-term use of glucocorticoids for those who are likely to benefit most, including those with prominent pain or extensive inflammatory disease. A clear plan for tapering and discontinuation should be established when using glucocorticoids.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For the purposes of this recommendation, the panel reviewed the use of short-term glucocorticoid therapy as a bridging therapy in JIA when used in conjunction with a disease modifying anti-rheumatic drug (DMARD). Although our search strategy permitted both systemic and intra-articular glucocorticoids in the intervention group, no randomised controlled studies were identified that used intra-articular glucocorticoids as the glucocorticoid intervention in addition to an adjunct DMARD in the intervention group. There is a separate living guideline recommendation that considers the choice of intra-articular glucocorticoid in JIA, with or without DMARD therapy (<a href="#jia-rec-7" onclick="openModal('jia-rec-7'); return false;">see recommendation on choice of intra-articular glucocorticoid</a>).</p>
<p>Only a single randomised controlled trial was identified that addressed the primary question of the use of a bridging systemic glucocorticoid for active JIA when used in conjunction with a DMARD <sup><a href="https://doi.org/10.1093/rheumatology/keab914" target="_blank" title="Bhardwaj et al.">65</a></sup>. While this study did not demonstrate a significant benefit of riding glucocorticoid, the panel exercised caution in drawing any definitive conclusions based on this single study. There were also several study characteristics that may limit its applicability to usual clinical practice in Australia. This includes the use of dexamethasone rather than prednisolone which is more commonly used in Australian paediatric rheumatology, as well as the dosing regimen of pulse IV dexamethasone every six weeks without any bridging oral glucocorticoids. In addition bridging oral and intra-articular glucocorticoids were allowed in both the intervention and control groups as needed which may have hampered the ability to detect a benefit from the intervention if one had been truly present.</p>
<p>The panel discussed the likely benefits and risks of the use of bridging glucocorticoids in JIA based on the experiences of the consumer advocates and the clinicians on the panel. Although there may be a significant negative impact on a young person&#x27;s wellbeing with prolonged glucocorticoid use, the immediate effect that glucocorticoids can have in severely active JIA means that patients would often still choose to proceed. There was also general consensus among clinicians from their experience that use of systemic glucocorticoids in severe JIA, when prescribed judiciously for a limited period of time with careful surveillance for adverse effects, is likely to be effective and generally well tolerated.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-6-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>The evidence considered by the panel for this recommendation specifically relates to the use of short-term adjunctive glucocorticoids in children and young people with juvenile idiopathic arthritis (JIA) who are commencing a disease modifying anti-rheumatic drug (DMARD) for active arthritis. Only one randomised controlled trial (RCT) was identified that met these criteria. This RCT compared pulse dexamethasone (3mg/kg intravenously for 3 days at 0, 6 &amp; 12 weeks) to placebo in DMARD naive patients with active JIA commencing methotrexate <sup><a href="https://doi.org/10.1093/rheumatology/keab914" target="_blank" title="Bhardwaj et al.">65</a></sup>.</p>
<p>Based on a single RCT of pulse dexamethasone versus placebo in young people with JIA commencing methotrexate:</p>
<ul>
<li>We are uncertain about the effect of short-term glucocorticoids in addition to DMARDs on the number of children and young people achieving ACR-Pedi 70 treatment response, serious adverse events, withdrawals due to adverse events, rescue glucocorticoid use, function or parent/patient wellbeing.</li>
<li>No studies were found that assessed the number of children and young people achieving clinically inactive disease / remission, overall pain or time to inactive disease / remission.</li>
</ul>
<p>Glucocorticoids have a broad mechanism of action and are useful treatments for a range of autoimmune diseases. There is good evidence that they have helpful disease-modifying properties in conditions such as rheumatoid arthritis <sup><a href="https://doi.org/10.1002/14651858.CD006356" target="_blank" title="Kirwan et al.">68</a></sup>. The use of glucocorticoids for JIA however, is largely based on anecdotal and observational evidence. Despite the lack of controlled studies, glucocorticoids have been proposed as an appropriate addition to other therapies as a â€œbridgingâ€ treatment. This strategy has particularly been suggested in the context of using slow acting DMARDs such as methotrexate and hydroxychloroquine <sup><a href="https://doi.org/10.1002/acr.20521" target="_blank" title="Huppertz et al.">67</a></sup>.</p>
<p>The adverse effect profile of glucocorticoids is well understood. These adverse effects are generally related to the dose and duration of treatment although there is significant variation between individuals. Common adverse effects include weight gain, emotional lability, hypertension and disordered sleep. Long term glucocorticoid use in children and young people can be particularly problematic given their effect on longitudinal growth and bone mineral density <sup><a href="https://doi.org/10.1007/s00296-018-4168-0" target="_blank" title="Batu et al. (2019)">75</a></sup>.</p>
<p>The panel felt strongly that the potential benefits of short-term glucocorticoid use should not be discounted, despite the lack of RCT evidence regarding the benefits of glucocorticoids in JIA. The panel noted the widespread use in current clinical practice and anecdotal evidence for the effectiveness of glucocorticoids as a bridging strategy. There may be a net benefit for some children and young people with JIA undergoing induction treatment, particularly those with significant pain due to arthritis and those with extensive disease. The adverse effects of high dose systemic steroids were noted, and the importance of close monitoring (of response and adverse effects) was highlighted. Intra-articular glucocorticoids were suggested as the preferred option for many patients given the lower risk of systemic adverse effects compared to systemic (oral, intravenous, intra-muscular) glucocorticoids.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very low</span></div><div class="etd-domain-text"><p>There was very low certainty evidence for all reported outcomes. This uncertainty was largely due to indirectness (inclusion of only one type of glucocorticoid) and imprecision (low number of trial participants, small event rates, wide confidence intervals that include worsening and improvement).</p>
<p>The evidence was confined to one study, and we are therefore unsure whether these findings can be extrapolated to other types of glucocorticoids, or glucocorticoids used in different doses or modes of administration.</p>
<p>There is one ongoing trial with anticipated completion date in 2023. This study is comparing concomitant intra-articular glucocorticoid injections versus no injections in patients commencing anti-tumour necrosis factor (anti-TNF) medications for JIA. The results of this trial may alter this recommendation.</p>
<p>The panel debated whether the certainty of evidence for the important outcomes should be considered as â€˜lowâ€™ or â€˜very lowâ€™. There was consensus that â€˜very lowâ€™ was more appropriate given the small scale of the included study and limited generalisability to other glucocorticoid types, doses and modes of administration.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>There are few published data specifically concerning the values and preferences for use of glucocorticoids in children and young people with JIA. However parents of children and young people with JIA have strong preferences for treatments that reduce pain and improve daily functioning regardless of the associated adverse effects <sup><a href="https://doi.org/10.1002/acr.21698" target="_blank" title="Burnett et al.">74</a></sup>.</p>
<p>More broadly, qualitative studies on JIA have identified a range of themes that are important to patients and their families including concerns about unrelenting and unpredictable pain, a focus on remission, a sense of control and a desire for knowledge. These themes were also reflected in the panel discussion. Active involvement in their own health decision-making has been suggested as a key strategy for addressing these issues for children and young people <sup><a href="https://doi.org/10.1002/acr.21695" target="_blank" title="Tong et al.">73</a></sup>.</p>
<p>It was agreed that most patients with significant pain are likely to accept glucocorticoids as an adjunctive treatment. The use of glucocorticoids to manage short term pain was strongly advocated by several members of the panel. It was also recognised that other patients, such as those with a history of significant glucocorticoid-associated adverse effects, may feel strongly against use of glucocorticoids. The importance of appropriate patient counselling, shared decision-making, monitoring of response and active treatment titration was highlighted.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Glucocorticoids are generally inexpensive.</p>
<p>There is a theoretical possibility that glucocorticoids may improve early response rates alongside first line DMARDs and subsequently reduce the need for second line therapies that are usually considerably more expensive. However the panel noted that this hypothesis remains unproven.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Given the widespread use and availability of glucocorticoids, there is unlikely to be significant inequity in accessing this treatment among patients also commencing a DMARD. The exception to this is intra-articular glucocorticoids which may be restricted to people who can access specialist services.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The range of different types, doses and durations of glucocorticoid treatment mean that they can be tailored and adjusted to an individual&#x27;s needs on the balance of benefits and harms. The rapid onset of action, particularly contrasted with slow-acting conventional synthetic DMARDs, is a very appealing characteristic of glucocorticoids. The potential risks of glucocorticoids must also be considered, particularly if used at high doses for prolonged periods <sup><a href="https://doi.org/10.1007/s00296-018-4168-0" target="_blank" title="Batu et al. (2019)">75</a></sup>.</p>
<p>Australian data show that approximately 50% of patients with non-systemic JIA are exposed to glucocorticoids in the first year of treatment but that only 10-15% remain on glucocorticoids at 12 months <sup><a href="https://doi.org/10.1186/s12969-018-0288-z" target="_blank" title="Tiller et al.">72</a></sup>. This suggests that glucocorticoids may be used quite sparingly in real world practice.</p>
<p>The panel felt that there is likely to be some variation among patients, clinicians and other stakeholders in the acceptability of the addition of steroids for JIA in patients starting a DMARD given the fine balance between benefits and harms. From a clinician and patient perspective, the benefits may outweigh the known adverse effects when used selectively and with a planned taper in most but not all circumstances.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>Glucocorticoids are readily available and are commonly used by specialists and non-specialists.</p>
<p>The panel did not anticipate any significant issue with the feasibility of using glucocorticoids in children and young people with JIA other than the potential limitations of intra-articular glucocorticoids as discussed above.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-6-practical">
                    <div class="content-section">
                        <ul>
<li>A treat-to-target approach within a shared decision-making framework is recommended for all patients with JIA, including with respect to the use of bridging glucocorticoids in the treatment of active disease.</li>
<li>Intra-articular glucocorticoids should be considered as the preferred option to systemic glucocorticoids depending on clinical circumstances, given they may have fewer systemic adverse effects.</li>
<li>In non-systemic JIA, if systemic glucocorticoid treatment is to be commenced, it should always be used in conjunction with introduction of a DMARD.</li>
<li>Oral prednisolone is currently the most routinely used systemic glucocorticoid in JIA and other rheumatic diseases in Australia, although other glucocorticoids (e.g. methylprednisolone, dexamethasone) may be suitable in certain situations.</li>
<li>Oral glucocorticoids should be used at the lowest necessary dose to achieve disease control for the shortest period necessary.</li>
<li>A written tapering plan should always be provided to patients and families.</li>
<li>In severe disease, an initial 'pulse' of intravenous glucocorticoids may be considered in conjunction with an oral prednisolone plan. Methylprednisolone is typically used for this purpose and is dosed up to 30mg/kg (up to 1,000mg) once daily for up to three consecutive days, though a duration of up to five consecutive days may be used in certain circumstances.</li>
<li>Any use of systemic glucocorticoids should be accompanied by appropriate surveillance for adverse effects including excess weight gain, mood disturbance, sleep disturbance and infection.</li>
<li>Prescribers of glucocorticoids should counsel patients and their families about the potential adverse effects of glucocorticoids. The Australian Rheumatology Association provides patient information sheets for medications commonly used in rheumatology, including for <a href="https://rheumatology.org.au/patient/Documents/Prednisolone_2022.pdf" target="_blank">prednisolone</a>.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-6-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 3: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people starting a DMARD for non-systemic juvenile idiopathic arthritis, are short-term adjunctive induction glucocorticoids safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1aJhn5HVdTXQqsYagsdoMSmPWfhP80B9t/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-6-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Dr Samuel Whittle (Chair)</span>
<span class="panel-member chair">Dr Sue Brennan (Facilitator)</span>
<span class="panel-member">Dr Neil Archer</span>
<span class="panel-member">Catherine Booth</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Emily Sheridan</span>
<span class="panel-member">Dr Joachim Tan</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Sarah Wilson</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">16 June 2022</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Short-term%20adjunctive%20induction%20glucocorticoids%20for%20non-systemic%20juvenile%20idiopathic%20arthritis" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240275" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-7">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Intra-articular therapies for juvenile idiopathic arthritis</div>
                    <h2 class="modal-title">Choice of intra-articular glucocorticoid</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-7', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-7', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-7', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-7', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-7', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-7-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with juvenile idiopathic arthritis receiving intra-articular glucocorticoid injection, we conditionally recommend use of triamcinolone hexacetonide in preference to other intra-articular glucocorticoid preparations.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For the purposes of this recommendation, the panel reviewed evidence on intra-articular triamcinolone hexacetonide for active juvenile idiopathic arthritis (JIA). A <a href="#jia-rec-6" onclick="openModal('jia-rec-6'); return false;">separate living guideline recommendation</a> has already been produced regarding the use of systemic glucocorticoid therapy in JIA.</p>
<p>Three randomised controlled trials were identified <sup><a href="https://doi.org/10.1016/j.ijom.2014.03.018" target="_blank" title="Olsen-Bergem et al.">81</a></sup><sup><a href="https://pubmed.ncbi.nlm.nih.gov/3330864/" target="_blank" title="Balogh et al.">82</a></sup><sup><a href="https://pubmed.ncbi.nlm.nih.gov/15252213/" target="_blank" title="Zulian et al.">83</a></sup>. The only trial that compared triamcinolone hexacetonide with placebo or no treatment was conducted in patients with arthritis affecting the temporomandibular joint specifically. Two trials compared triamcinolone hexacetonide with alternative glucocorticoid preparations in more commonly affected peripheral joints in JIA. In general, evidence regarding the benefits and harms of intra-articular glucocorticoid therapy in people with JIA is of very low certainty. However, there was low certainty evidence from one trial that although there may be little difference between different glucocorticoid preparations in terms of the initial response to glucocorticoid injection, triamcinolone hexacetonide may reduce the number of joints with recurrence of arthritis compared to triamcinolone acetonide over a twelve month period. The more durable response to triamcinolone hexacetonide compared with other glucocorticoid preparations is consistent with its pharmacokinetic properties (as a low-solubility preparation that may persist longer in the joint).</p>
<p>The panel felt that intra-articular steroids are generally acceptable to families given the rapid symptomatic relief that they may provide. Furthermore, the panel felt that the potential for a more durable response from triamcinolone hexacetonide was an important consideration in recommending it as the first choice intra-articular glucocorticoid in most cases. Despite the logistical complexities involved in the use of triamcinolone hexacetonide, the panel felt that the putative benefits still warrant using it in preference to other alternatives. In healthcare settings where triamcinolone hexacetonide is not available then other intra-articular glucocorticoids such as triamcinolone acetonide or methylprednisolone are reasonable alternatives.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-7-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p><strong>Benefits</strong></p>
<ul>
<li>Triamcinolone hexacetonide with arthrocentesis (joint aspiration) may have little or no effect on overall pain compared to arthrocentesis alone in temporomandibular joint arthritis</li>
<li>Triamcinolone hexacetonide may have little or no effect on the number of joints with initial improvement compared to triamcinolone acetonide</li>
<li>Triamcinolone hexacetonide may reduce the number of joints with recurrence of arthritis at 12 months compared to triamcinolone acetonide</li>
</ul>
<p><strong>Harms</strong></p>
<ul>
<li>There were no systemic adverse events with triamcinolone hexacetonide, triamcinolone acetonide or betamethasone</li>
<li>We are uncertain whether triamcinolone hexacetonide resulted in more or fewer localised adverse events compared to alternative glucocorticoids due to the very small event rate</li>
</ul>
<p>No studies were found that assessed the number of participants switching, commencing or adding disease modifying anti-rheumatic drugs (DMARDs), treatment response, proportion with recurrence of arthritis in injected joints, systemic adverse events, or localised adverse events in trials comparing intra-articular triamcinolone hexacetonide with no treatment for temporomandibular joint arthritis. Similarly, no studies were found that compared triamcinolone hexacetonide with no treatment for any other joint.</p>
<p>No studies were found that compared intra-articular triamcinolone hexacetonide to placebo.</p>
<p>No studies were found that assessed the number of participants switching, commencing or adding DMARDs, mean function, or mean overall pain in trials comparing triamcinolone hexacetonide with an alternative intra-articular glucocorticoid.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very low</span></div><div class="etd-domain-text"><p>The certainty of evidence that compared intra-articular triamcinolone hexacetonide to no treatment was deemed very low for overall pain in the one study identified <sup><a href="https://doi.org/10.1016/j.ijom.2014.03.018" target="_blank" title="Olsen-Bergem et al.">81</a></sup>. This was due to serious risk of bias from selection and reporting bias, serious imprecision due to a small number of participants from a single study, and serious indirectness (only the temporomandibular joint was studied).</p>
<p>The certainty of evidence that compared intra-articular triamcinolone hexacetonide with an alternative intra-articular glucocorticoid was deemed low for treatment response and the proportion of participants with recurrence of arthritis in injected joint in the one study identified <sup><a href="https://pubmed.ncbi.nlm.nih.gov/15252213/" target="_blank" title="Zulian et al.">83</a></sup>. This was due to serious risk of bias from potential selection bias and unit of analysis issues, and serious imprecision due to a small number of events from a single study and a low number of participants. There were also unit of analysis issues in this study due to randomisation occurring per joint rather than per individual participant. This meant that some individual participants with a higher number of active joints than others receiving intra-articular steroid injection may have skewed the overall outcomes slightly towards their outcomes that were measured.   It is uncertain whether this bias may have affected the overall results.</p>
<p>The certainty of evidence that compared intra-articular triamcinolone hexacetonide with an alternative intra-articular glucocorticoid was deemed very low for systemic adverse events and localised adverse events in the two studies identified <sup><a href="https://pubmed.ncbi.nlm.nih.gov/3330864/" target="_blank" title="Balogh et al.">82</a></sup><sup><a href="https://pubmed.ncbi.nlm.nih.gov/15252213/" target="_blank" title="Zulian et al.">83</a></sup>. This was due to serious risk of bias from potential selection bias,  unit of analysis issues, lack of events and low number of participants studied.</p>
<p>Based upon the quality of the evidence, the panel consensus was that the overall certainty of evidence was very low.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">No substantial variability expected</span></div><div class="etd-domain-text"><p>There is little published evidence on the values and preferences of children and young people with JIA regarding the outcomes of intra-articular treatments. Parents of children and young people with JIA  prefer interventions that may reduce pain and improve daily function and participation <sup><a href="https://doi.org/10.1002/acr.21698" target="_blank" title="Burnett et al.">74</a></sup>.</p>
<p>Members of the panel considered that, in general, the potential improvement in pain and function associated with intra-articular triamcinolone hexacetonide would outweigh concerns about the discomfort of the injection and low risk of other adverse events associated with the procedure, particularly if it  were to lead to rapid improvements in symptoms. When presenting this treatment option as the alternative to commencing systemic glucocorticoid therapy or earlier commencement of DMARD therapy in milder disease, many may prefer this over having to administer a regular long-term medication or requiring intra-articular glucocorticoid injections with an alternative glucocorticoid preparation more frequently.</p>
<p>Although younger patients may not be able to tolerate a painful procedure, intra-articular triamcinolone hexacetonide injections are routinely given with adjunct local anaesthesia, sedation and/or general anaesthesia  to minimise pain and trauma. Injections are usually given by paediatric rheumatologists, trained and experienced in providing intra-articular injections in children and young people with JIA.</p>
<p>The panel expected that there would be no substantial variability in values and preferences related to the use of intra-articular triamcinolone hexacetonide. The consensus view was that most patients and families would weigh the potential benefits in terms of improvement in arthritis symptoms and overall disease control more highly than the potential discomfort or minor adverse effects associated with the procedure.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel noted that there may be important resource considerations specific to triamcinolone hexacetonide. Other intra-articular glucocorticoid preparations such as triamcinolone acetonide, methylprednisolone acetate, and hydrocortisone are more widely available in the hospital and clinic setting, due to their availability on the Australian Register of Therapeutic Goods (ARTG) and are more commonly used  in the treatment of adult conditions such as rheumatoid arthritis, osteoarthritis, and crystal-induced arthropathies. This is not the case with triamcinolone hexacetonide, which is not on the ARTG and is used almost exclusively in the management of JIA.</p>
<p>The direct monetary cost of triamcinolone hexacetonide to individual hospitals offering this intervention is dependent on pharmaceutical provider offering the medication and the negotiated price by pharmacies accessing the medicine for patients with JIA. As a result, the monetary cost of triamcinolone hexacetonide compared to other intra-articular glucocorticoid preparations can vary. There is also no subsidy for triamcinolone hexacetonide from the Pharmaceutical Benefits Scheme (PBS). As a result, the cost of purchase is directly absorbed by individual public hospitals offering this intervention to patients. In the case of patients receiving this medication through the private healthcare system, the patients themselves may be required to bear the cost of the medication without subsidy.</p>
<p>Further, triamcinolone hexacetonide is not manufactured in Australia or routinely stocked by local wholesalers, and is therefore imported in small quantities. This may lead to a larger carbon footprint associated with the use of  triamcinolone hexacetonide compared to other intra-articular glucocorticoid preparations that are produced or supplied in bulk in Australia.</p>
<p>Triamcinolone hexacetonide is also not a widely-used medicine for any other indication other than JIA. As a result, it may not be routinely available in pharmacies in smaller peripheral hospitals and private community pharmacies. Non-tertiary sites that may potentially be able to offer intra-articular glucocorticoid injections to young people with JIA, such as interventional radiology centres and regional orthopaedic departments, may not be able to access triamcinolone hexacetonide for this reason.</p>
<p>Procedural use of intra-articular glucocorticoid therapy may also entail adjunct costs required to perform the procedure. These costs may include those related to performing the procedure under anaesthesia such as theatre clinical staff requirements, equipment, and the costs related to anaesthetic medications administered.</p>
<p>This, and the additional financial and logistical challenges associated with accessing triamcinolone hexacetonide as described above, may have implications for the availability of this medication in the private practice setting. Many private healthcare providers will typically refer patients to public-funded paediatric rheumatology centres specifically for intra-articular glucocorticoid injections, thus placing some additional burden on public healthcare services.</p>
<p>There are no cost-effectiveness data comparing triamcinolone hexacetonide with other intra-articular glucocorticoid preparations. However, it is plausible that the  additional costs through access difficulties described above may be offset by improvements in function, the  potential for reduced use of pain-relieving medication and DMARD medications including expensive biologic therapies, and the potential reduction in the frequency of repeat intra-articular procedures due to the possible long-acting efficacy of triamcinolone hexacetonide compared to other intra-articular glucocorticoids.</p>
<p>The panel considered the issues surrounding resources at length and agreed on a judgment of â€œimportant issues, or potential issues not investigated.â€ While most felt that it is a medicine that ultimately can be made available to all children and young people with JIA in Australia through specific tertiary paediatric rheumatology services, there are clear challenges and barriers that could be addressed.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Intra-articular injection with triamcinolone hexacetonide is available to any children or young person with JIA with access to a children&#x27;s rheumatology service. However patients who live in remote and regional communities may need to travel to metropolitan centres to access this intervention due to the paucity paediatric rheumatologists, specialist nurses and/or paediatric anaesthetists in remote and regional hospitals as well as the difficulties associated with accessing this particular glucocorticoid preparation.</p>
<p>Lack of easy access to triamcinolone hexacetonide in remote and regional areas has the potential to lead to differences in how these patients are otherwise managed. If patients are unable to travel to a children&#x27;s rheumatology service and unable to access triamcinolone hexacetonide locally, they may potentially receive systemic glucocorticoids or earlier prescription of DMARD therapies as an alternative treatment measure.</p>
<p>After some discussion, the panel agreed on a judgement of â€œimportant issues, or potential issues not investigated&quot; based on the above issues.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>It is likely that most children and young people with JIA as well as their carers would find intra-articular triamcinolone hexacetonide therapy to be an acceptable treatment modality. This is due to the rapid onset of effect in treating active arthritis, the safety profile of the procedure, the availability of sedation and anaesthesia for younger patients who may be unable to tolerate the procedure, and the potential that use of the procedure will lessen the requirement for systemic glucocorticoids and/or immunosuppressive DMARDs. However, the panel emphasised that for many children and young people, intra-articular procedures are challenging, regardless of the level of anaesthesia or sedation offered, and may be associated with significant anxiety.</p>
<p>The intervention is widely accepted by paediatric rheumatologists in Australia. Procedural expertise in intra-articular glucocorticoid therapy is a standard skillset and forms an integral part of subspecialty training in paediatric rheumatology.</p>
<p>The panel considered that acceptability of intra-articular injection of triamcinolone hexacetonide may vary and agreed upon a judgment of â€œimportant issues, or potential issues not investigated.â€</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>All Australian public paediatric tertiary centres with a rheumatology service have facilities to provide intra-articular triamcinolone hexacetonide injections to children and young people with JIA. It is however not easily accessible for private healthcare providers in community clinics, nor is it available for purchase in smaller pharmacies.</p>
<p>As discussed in â€˜Resourcesâ€™, triamcinolone hexacetonide lacks registration on the Australian Register of Therapeutic Goods (ARTG). As a result, paediatric tertiary centres wishing to access this medicine for patients require individual clinicians to undertake a complex process to be able to prescribe and import it for patients.</p>
<p>The panel therefore decided on a judgment of â€œimportant issues, or potential issues not investigatedâ€, based on the significant feasibility issues present.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-7-practical">
                    <div class="content-section">
                        <ul>
<li>The administration of triamcinolone hexacetonide should only be offered after a clinical diagnosis is made of active inflammatory arthritis in a child or young person. Triamcinolone hexacetonide is not recommended for other musculoskeletal conditions of childhood, including sports injuries, non-inflammatory biomechanical joint pain, Ehlers-Danlos Syndrome and other joint hypermobility syndromes, or chronic pain syndromes. Triamcinolone hexacetonide may potentially cause significant harm in children and young people if administered into an undiagnosed septic joint.</li>
<li>Following the administration of intra-articular triamcinolone hexacetonide, most clinicians would recommend that patients avoid engaging in high impact activities for 24 hours after the procedure.</li>
<li>Certain sites for intra-articular injection (hip joint, sacroiliac joint) may be difficult to access and often require radiological guidance with ultrasound or other imaging modalities.</li>
<li>A temporary plaster cast and/or physiotherapy may be considered in some patients after an intra-articular injection to help correct the position of the joint when there is a substantial fixed flexion deformity.</li>
<li>Methods of anaesthesia (including general, inhaled, and local anaesthetic agents) should be considered and tailored to each patient based on their chronological age, developmental age, co-morbidities, pre-disposition to procedural anxiety, and type and number of joint/s receiving intra-articular injection.</li>
<li>Systemic DMARD therapy with methotrexate or other agents should be considered in conjunction with intra-articular glucocorticoid therapy, unless only mild oligo-articular disease is present.</li>
<li>In patients with a large number of joints affected, who require frequent injection of the same joint, or who have complex joint disease, systemic glucocorticoid therapy may be preferred to multiple intra-articular injections.</li>
<li>Intra-articular steroids are gradually absorbed systemically for a number of weeks after injection. Systemic side-effects should be considered and anticipated, particularly when large doses of intra-articular steroids are used <sup><a href="https://pubmed.ncbi.nlm.nih.gov/3948470/" target="_blank" title="Derendorf et al.">92</a></sup>.</li>
<li>There is no consensus on dosing for triamcinolone hexacetonide per joint. One dosing regimen for triamcinolone hexacetonide used commonly in major paediatric rheumatology centres is 1mg/kg/joint to a maximum of 40mg for large joints (knees, hips, and shoulders), 0.5mg/kg/joint to a maximum of 20mg for medium sized joints (ankles, wrists, elbows), up to 10mg for the temporomandibular joint, and 0.5-2mg/joint for small joints (metacarpophalangeal, metatarsophalangeal, interphalangeal) <sup><a href="https://pubmed.ncbi.nlm.nih.gov/12598375/" target="_blank" title="Cleary et al.">91</a></sup><sup><a href="https://doi.org/10.1016/j.ijom.2014.03.018" target="_blank" title="Olsen-Bergem et al.">81</a></sup><sup><a href="https://doi.org/10.1016/j.joms.2011.11.003" target="_blank" title="Stoll et al.">99</a></sup>.</li>
<li>Due to the low solubility of triamcinolone hexacetonide, there is a hypothetical increased risk of local adverse events such as steroid atrophy, particularly for small joints (e.g., metacarpophalangeal, metatarsophalangeal and interphalangeal joints). As a result, some clinicians may prefer to use an alternative intra-articular glucocorticoid (such as triamcinolone acetonide or methylprednisolone) when injecting these joints.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-7-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 4b: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis receiving intra-articular glucocorticoid injection, is triamcinolone hexacetonide more effective and/or safer than other preparations?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1Ko3i2pszlPvrRTX1PTTC5mE5vkSBFoVM/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-7-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Dr Samuel Whittle (Chair)</span>
<span class="panel-member">Prof Rachelle Buchbinder</span>
<span class="panel-member">Dr Helen Cooley</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Dr Grainne Murray</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Emily Sheridan</span>
<span class="panel-member">Dr Joachim Tan</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Sarah Wilson</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">15 September 2022</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Triamcinolone%20hexacetonide%20versus%20triamcinolone%20acetonide%20for%20intra-articular%20injection%20in%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240276" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-8">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Intra-articular therapies for juvenile idiopathic arthritis</div>
                    <h2 class="modal-title">Use of anaesthesia for intra-articular injection</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-8', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-8', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-8', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-8', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-8', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-8-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with juvenile idiopathic arthritis receiving intra-articular joint injection, consider use of topical and/or injectable anaesthesia based on a shared decision between patient, carer and clinician.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For the purposes of this recommendation, the panel reviewed the evidence associated with the use of local anaesthetic agents for intra-articular glucocorticoid injection. While the search strategy was designed  to identify studies assessing any combination of local anaesthesia administered topically, intra-dermally, subcutaneously or intra-articularly, only two studies were identified <sup><a href="https://pubmed.ncbi.nlm.nih.gov/12610822/" target="_blank" title="Uziel et al.">84</a></sup><sup><a href="https://doi.org/10.1186/s12969-015-0034-8" target="_blank" title="Weiss et al.">85</a></sup>. One study compared topical anaesthesia to placebo <sup><a href="https://pubmed.ncbi.nlm.nih.gov/12610822/" target="_blank" title="Uziel et al.">84</a></sup> and one compared topical and injected local anaesthesia to topical anaesthesia alone <sup><a href="https://doi.org/10.1186/s12969-015-0034-8" target="_blank" title="Weiss et al.">85</a></sup>. Overall the evidence provides very low certainty regarding the benefits and harms of local or topical anaesthesia. The addition of subcutaneous local anaesthesia to topical anaesthetic may improve patient global assessment of wellbeing. Neither trial measured function, treatment success or procedure completion rate.</p>
<p>The existing evidence may have limited applicability to current practice. Many practitioners choose to use local anaesthesia in addition to other strategies such as oral analgesia prior to the the procedure and/or sedation (e.g., inhaled nitrous oxide) during the procedure, minimise procedural pain. The trials only assessed the benefits and harms of local anaesthesia for intra-articular glucocorticoid injection into the knee which may limit the generalisability of the trial results to other joint sites. The knee is the most commonly injected joint by rheumatologists and also considered to be the least technically challenging.</p>
<p>Topical anaesthesia agents such as Eutectic Mixture of Local Anesthetics (EMLAâ„¢) cream are easy to administer, cause little to no discomfort and may provide reassurance to the young person undergoing the procedure that steps have been taken to minimise their discomfort.</p>
<p>There is wide variation in the use of combination intra-articular local anaesthesia and glucocorticoid intra-articular injection. Some clinicians may use no intra-articular local anaesthesia, some may inject the local anaesthetic first, some mix the two together, and some may inject the local anaesthetic immediately after the glucocorticoid. While mixing intra-articular local anaesthesia with glucocorticoid is widely believed to reduce the risk of post-procedure pain and inflammation, this remains unproven. There are no randomised controlled trials comparing the outcomes of intra-articular glucocorticoid Injection with or without concomitant local anaesthesia in patients with JIA or in adults with inflammatory arthritis. There is also uncertainty about whether any benefits of intra-articular local anaesthesia vary by the intra-articular glucocorticoid preparation is used.</p>
<p>Many children and young people who would be unable to tolerate an intra-articular procedure while awake or under light sedation will instead undergo intra-articular glucocorticoid injection under general anaesthesia. It is uncertain whether local anaesthesia provides any added benefit in this population of patients.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-8-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p><strong>Benefits</strong></p>
<ul>
<li>We are uncertain whether topical anaesthesia improves procedural pain for intra-articular injections compared to placebo.</li>
<li>The addition of subcutaneous local anaesthesia to topical anaesthetic may or may not improve procedural pain.</li>
<li>The addition of subcutaneous local anaesthesia to topical anaesthetic may improve patient global assessment of wellbeing.</li>
</ul>
<p><strong>Harms</strong></p>
<ul>
<li>We are uncertain whether topical anaesthesia results in serious adverse events as there were none identified in participants receiving topical Eutectic Mixture of Local Anesthetics (EMLAâ„¢) or placebo.</li>
</ul>
<p>No studies comparing topical anaesthesia with placebo were found that assessed treatment success, procedure completion rate, global assessment of wellbeing, total adverse events, or function.</p>
<p>No studies comparing injectable anaesthesia in conjunction with topical anaesthesia with topical anaesthesia alone were found that assessed treatment success, procedure completion rate, total adverse events, function, serious adverse events or total adverse events.</p>
<p>No studies were found that assessed the safety and efficacy of intra-articular local anaesthesia.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very low</span></div><div class="etd-domain-text"><p>The evidence for all available outcomes that compared topical anaesthesia with placebo was deemed very low for procedural pain and serious adverse events <sup><a href="https://pubmed.ncbi.nlm.nih.gov/12610822/" target="_blank" title="Uziel et al.">84</a></sup>. This was due to serious risk of bias (selection and reporting) and very serious imprecision due to having data from a single study with a very low number of participants, leading to wide confidence intervals and a low number of events.</p>
<p>The evidence for all available outcomes that compared a combination of injectable and topical anaesthesia with topical anaesthesia alone was deemed low for procedural pain and participant global assessment of wellbeing <sup><a href="https://doi.org/10.1186/s12969-015-0034-8" target="_blank" title="Weiss et al.">85</a></sup>. This was due to serious risk of bias (potential detection and selection bias) and imprecision due to there being data available from only one study with a low number of participants.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>The panel discussed the various issues surrounding values and preferences of children and young people with JIA and their carers with respect to the use and various forms of administration of local anaesthetic agents during intra-articular glucocorticoid procedures. The potential for a less painful experience, less procedural anxiety, and an improved procedural success rate is likely to be weighted highly by children and young people with JIA and their carers.</p>
<p>The panel noted that individuals who are particularly averse to needles may prefer to avoid an additional injection of local anaesthesia. There is also likely to be considerable variability in values and preferences between different clinical settings, including the age of the patient, the use of sedation, the size of the joint, and the number of joints injected in a single session.</p>
<p>After discussion by the panel regarding this range of issues, the panel agreed on a judgement of â€œimportant issues, or potential issues not investigatedâ€.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>Topical and injectable anaesthetic agents are generally inexpensive. Use of local anaesthetic agents may theoretically reduce the need for more resource intensive interventions, such as general or inhaled anaesthesia, which generally would require additional trained clinical staff and resources. Topical and injectable anaesthetic agents are used for a broad range of indications and are generally easily accessed across healthcare settings.</p>
<p>However, other important issues Include the lag period of 30-60 minutes before adequate local anaesthesia is achieved for many topical anaesthetic agents. This may require  additional time of clinical staff. Some carers may be able to perform this procedure at home, although this requires specific instruction and prescription and risks incorrect administration. Some panel members noted that temporary supply shortages of topical anaesthetic agents have also occurred on occasion at their clinical site.</p>
<p>Although these issues were generally deemed not insurmountable, the panel agreed on a judgment of â€œimportant issues, or potential issues not investigatedâ€.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>The panel did not perceive any significant equity issues relating to the provision of local injection or topical anaesthesia among children and young people receiving intra-articular glucocorticoid injections. The panel considered that there may potential variation in the degree of local anaesthesia that is offered to minimise discomfort, and this may be dependent on age, neurodevelopmental status, psychological co-morbidities and setting. Private providers may consider referring patients to public centres if there is a significant financial cost difference for patients. Some patients living in regional areas may prefer to have a procedure done with a private radiology service rather than travel to a metropolitan site, and there may be variability in how local anaesthesia is offered in those centres. Overall, the panel felt that these issues were unlikely to have a substantial impact on health equity among  children and young people with JIA.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The panel considered that topical anaesthesia, which can be applied without significant discomfort, is likely to be acceptable to most young people unless they have a pre-existing allergy to the anaesthetic agent. One common drawback is that topical anaesthesia needs to be applied 30-60 minutes before the intra-articular glucocorticoid injection to achieve its optimal anaesthetic effect <sup><a href="https://pubmed.ncbi.nlm.nih.gov/1430539/" target="_blank" title="Lycka et al. (1992)">93</a></sup>. Topical anaesthesia is usually administered by a nurse or rheumatologist rather than carers prior to hospital attendance. Application of topical anaesthesia in the hospital setting may  lead to increased anxiety while awaiting the procedure for some children and young people. Additionally, it is not uncommon for neurodivergent young people, such as those with heightened sensory perception, to find administration of anaesthesia creams to be unpleasant.</p>
<p>There is also uncertainty regarding the acceptability of the use of locally injected anaesthetic agents among children and carers, as this requires an an additional needle to be inserted into the skin. Local injection of anaesthetic agents also generally cause some discomfort which some young people may find as unpleasant as the intra-articular glucocorticoid injection itself, although this would likely vary depending on type of joint being injected.</p>
<p>There may also be variation among clinicians and possibly patients and their carers regarding the acceptability of combining local anaesthesia with intra-articular glucocorticoid, due to the uncertainty about whether this provides any additional benefit. The panel therefore agreed on a judgment of â€œimportant issues, or potential issues not investigatedâ€.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">No important issues with the recommended alternative</span></div><div class="etd-domain-text"><p>All paediatric tertiary centres in Australia with a paediatric rheumatology service have facilities to provide intra-articular glucocorticoid injections and local anaesthesia to children and young people with JIA. The panel considered that there were no important issues related to its feasibility.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-8-practical">
                    <div class="content-section">
                        <ul>
<li>The administration of local anaesthesia in conjunction with intra-articular glucocorticoid injections should be performed by specialists with expertise performing these procedures in children and young people with JIA.</li>
<li>Local anaesthesia should be available to all patients undergoing intra-articular injections and should be offered within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances. The utility of local anaesthesia is likely to be dependent on multiple factors including the child or young person's age, developmental status, experience with prior intra-articular injections and the number and type of joints to be injected.</li>
<li>Procedural pain management strategies should always be used for intra-articular injections. These include consent and education about the procedure, planning and preparation, and effective communication through the procedure.</li>
<li>Additional methods of sedation and/or anaesthesia, including but not limited to inhaled nitrous oxide, midazolam or ketamine, should be considered and tailored to each patient. It should be noted that nitrous oxide has a large carbon footprint and other drugs may be preferred.</li>
<li>Paracetamol or non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, naproxen, etc) can also be given to patients around the time of intra-articular glucocorticoid injection.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-8-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 4a: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis receiving intra-articular glucocorticoid injection, is local anaesthesia safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1xYsZf5OeApuyCc6wdIqvGdELPGLGUPhm/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-8-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Dr Samuel Whittle (Chair)</span>
<span class="panel-member">Catherine Booth</span>
<span class="panel-member">Prof Rachelle Buchbinder</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Dr Grainne Murray</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Emily Sheridan</span>
<span class="panel-member">Dr Joachim Tan</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Sarah Wilson</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">1 September 2022</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Local%20anaesthesia%20for%20joint%20injection%20in%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240276" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-9">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Non-pharmacological interventions for JIA</div>
                    <h2 class="modal-title">Foot orthoses in children and young people with juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-9', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-9', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-9', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-9', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-9', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-9-recommendation">
                    <span class="strength-badge conditional-against">âŠ– Conditional Recommendation Against</span>
                    <div class="recommendation-box"><p>Do not routinely use foot orthoses in children and young people with JIA. </p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>For this recommendation, the panel considered evidence from randomised controlled trials (RCTs) of various orthotic interventions (including standardised footwear) in children and young people with juvenile idiopathic arthritis (JIA). The panel noted the complexity inherent in summarising trial data for these interventions due to the different types of footwear and orthotic interventions, the potential for their use in combination, and the differences in the target population (e.g. those with or without painful feet) and outcome measures.</p>
<p>The panel considered the following types of interventions:</p>
<ul>
<li><strong>Standardised footwear</strong> - often athletic shoes, which may incorporate some of the putative beneficial features of orthoses, including support or cushioning, but which are not customised to the individual wearer. Different brands or models of shoes may offer different features. Importantly, shoes may also be worn with or without additional orthotic devices.</li>
<li><strong>Prefabricated foot orthoses</strong> - devices that are pre-made, standardised, and available for immediate use off-the-shelf. Different devices may offer different features and fit.</li>
<li><strong>Customised prefabricated foot orthoses</strong> - generic pre-made devices that are adapted to the individual by a podiatrist or other provider, typically at the point of care.</li>
<li><strong>Customised foot orthoses</strong> - bespoke orthoses tailored to each of the individual's feet, typically based on casting or other biomechanical or imaging assessment, and manufactured to order.</li>
</ul>
<p>The panel noted that there is a large price spectrum for foot orthoses, from relatively inexpensive off-the-shelf prefabricated foot orthoses to highly customised foot orthoses that may be more than five times as expensive (an indicative price for prefabricated foot orthoses in Australia is approximately $150, compared to as much as $1000 for customised foot orthoses).</p>
<p>There is also often a large price range for footwear, which may often reflect aesthetic, fashion or other economic influences rather than design features, comfort or durability. There are also a number of potential providers of customised orthoses including healthcare professionals (such as podiatrists and orthotists) and commercial footwear and orthotic vendors; the latter in particular are often associated with considerable out-of-pocket costs to families.</p>
<p>The panel reviewed evidence from four RCTs which provided low certainty evidence that customised foot orthoses (including both customised or adapted prefabricated devices or fully customised orthoses) may have little or no effect on pain, function or global assessment of wellbeing compared to either usual care or a sham orthotic device. There was very low certainty evidence regarding the effect of either customised or prefabricated foot orthoses versus standardised footwear, or comparing the various types of foot orthoses. There was very low certainty evidence regarding the potential adverse effects of any type of orthotic or footwear intervention.</p>
<p>While the panel considered that important harms were unlikely, there was concern regarding the significant out-of-pocket costs associated with foot orthoses, particularly those that are highly customised. Other concerns included the need for additional visits to providers for highly customised devices, which may add further cost and inconvenience, and the potential impact on shoe choice, which may have practical and social implications for children and young people with JIA.</p>
<p>In general, the panel considered that the paucity of evidence in favour of a beneficial effect of any footwear or orthotic intervention on important outcomes such as pain or function suggests that routine use of any form of foot orthosis in children and young people with JIA is not required, and that, in particular, the use of very expensive interventions is not supported by evidence and should be discouraged.</p>
<p>This living recommendation is conditional and therefore is sensitive to individual circumstances and preferences. The panel noted that there may be individuals for whom a trial of an orthotic intervention is warranted. In such cases, a relatively low-cost intervention (such as supportive footwear or prefabricated or adapted prefabricated foot orthoses) may be preferred to fully customised foot orthoses or other expensive options, and should be tailored to the individual patientâ€™s needs and preferences, including footwear choice, and outcomes, particularly impact on pain and participation.</p>
<p>The panel emphasised the need for further research on this topic, particularly in regard to the comparison between standardised footwear (e.g. athletic shoes) and inexpensive orthoses (e.g. simple adapted prefabricated devices) and their use in combination. This living recommendation will be updated if relevant new evidence emerges.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-9-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p>We considered the following types of interventions:</p>
<ul>
<li><strong>Standardised footwear</strong> - often athletic shoes, which may incorporate some of the putative beneficial features of orthoses, including support or cushioning, but which are not customised to the individual wearer. Different brands or models of shoes may offer different features. Importantly, shoes may also be worn with or without additional orthotic devices.</li>
<li><strong>Prefabricated foot orthoses</strong> - devices that are pre-made, standardised, and available for immediate use off-the-shelf. Different devices may offer different features and fit.</li>
<li><strong>Customised prefabricated foot orthoses</strong> - generic pre-made devices that are adapted to the individual by a podiatrist or other provider, typically at the point of care.</li>
<li><strong>Customised foot orthoses</strong> - bespoke orthoses tailored to each of the individual's feet, typically based on casting or other biomechanical or imaging assessment, and manufactured to order.</li>
</ul>
<p>In children and young people with painful feet due to juvenile idiopathic arthritis:</p>
<p><strong>Benefits</strong></p>
<ul>
<li>Customised and customised prefabricated foot orthoses, compared to usual care or sham orthoses, may have little or no effect on mean foot pain, mean foot function, mean functional assessment and mean participant-reported global assessment of wellbeing.</li>
</ul>
<p><strong>Harms</strong></p>
<ul>
<li>We are uncertain whether customised and customised prefabricated foot orthoses, compared to usual care or sham orthoses, result in more withdrawals from treatment due to any reason or in more children and young people reporting adverse events.</li>
</ul>
<p>We are uncertain of the benefits and harms of prefabricated foot orthoses, or of standardised footwear compared to foot orthoses, due to the very low certainty evidence. Data on the number of children and young people with active arthritis were not reported in the available trials.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Low</span></div><div class="etd-domain-text"><p>The certainty of evidence was low to very low for all outcomes.</p>
<p>For the comparison, custom-made foot orthoses versus sham orthoses or usual medical care, evidence was low for foot pain, foot function, functional assessment and global assessment of wellbeing. Evidence was downgraded due to the potential for performance and detection bias from unblinded participants in one trial, and for imprecision.</p>
<p>For other comparisons, the evidence for foot pain and foot function was very low certainty, due to the potential for bias, imprecision, and indirectness arising from the short follow-up time and the unknown validity of the measure for foot function (FFI) in children and young people. Functional assessment and global assessment of wellbeing were not reported in these comparisons.</p>
<p>For all comparisons, the evidence was very uncertain for the number of withdrawals from treatment for any reason and for the number of children and young people reporting adverse events, due to bias and very low event rates.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>Children and young people with JIA affecting the feet identify pain as the most important symptom <sup><a href="https://doi.org/10.1016/j.apmr.2012.07.007" target="_blank" title="Hendry et al.">121</a></sup>. Interference with mobility, function and participation are also reported as highly important. There may be a trade-off between the potential beneficial effects of foot orthoses on pain and function, versus the potential impact of custom footwear on the comfort, convenience, utility, and social and aesthetic aspects of footwear, including shoe choice <sup><a href="https://doi.org/10.1177/0309364620952906" target="_blank" title="Lahoud et al.">122</a></sup><sup><a href="https://doi.org/10.1016/j.apmr.2022.10.010" target="_blank" title="Orlando et al.">123</a></sup><sup><a href="https://doi.org/10.1097/PXR.0000000000000145" target="_blank" title="Marcotte et al.">124</a></sup>. In a qualitative study of patient, parent, and practitioners&#x27; perceptions of foot problems in JIA, choice of footwear was identified as &#x27;extremely important&#x27; by participants <sup><a href="https://doi.org/10.1016/j.apmr.2012.07.007" target="_blank" title="Hendry et al.">121</a></sup>.</p>
<p>In a discrete choice experiment of parents&#x27; preferences for foot care in JIA, improvement in daily function, pain and mobility, as well as â€˜ability to wear desired footwearâ€™, were found to be the most important attributes, however children and young people with JIA were not included in this study <sup><a href="https://doi.org/10.1186/1757-1146-7-10" target="_blank" title="Hendry et al.">125</a></sup>.</p>
<p>The relative importance afforded to the effect of foot orthoses on pain and function versus the impact on choice or use of footwear may vary between individuals and within individuals over time, according to various factors including age, disease activity, participation in sport or work, and individual preferences.</p>
<p>The panel discussed the difficulty that families may face in weighing any potential benefits of a non-pharmacological intervention such as custom footwear in a child or young person with JIA, particularly those experiencing foot pain despite pharmacotherapy, against the cost, inconvenience, and impact on shoe choice associated with foot orthoses, particularly customised foot orthoses.</p>
<p>The panel noted that, practically, footwear is always required for any foot orthosis to be worn, and that a well-selected shoe design may be therapeutic on its own.</p>
<p>The panel concluded that there is likely to be substantial variability in how these outcomes are weighted, both between individuals, and within individuals over time or in respect to different orthotic options (e.g. supportive footwear, prefabricated foot orthoses, adapted prefabricated devices, or highly customised foot orthoses).</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important negative issues</span></div><div class="etd-domain-text"><p>We did not identify any cost-effectiveness data regarding the use of foot orthoses in children and young people with JIA. The cost of orthoses varies, and is typically much higher for custom foot orthoses than for prefabricated foot orthoses. There may be additional direct costs to families related to the use of foot orthoses, including consultation(s) with a podiatrist or other healthcare providers, additional or altered footwear, and indirect costs, including additional time off work for carers. The impact of these costs is likely to vary between individuals.</p>
<p>We did not identify any data regarding the impact of foot orthoses on the environment.</p>
<p>The panel discussed the cost implications of customised footwear and orthoses at length. It was noted that the various orthotic options are associated with a wide cost range and that, in particular, highly customised orthoses often attract very high out-of-pocket costs. Many forms of athletic footwear also incorporate some orthotic features, but there is scant evidence regarding the interaction between specific shoe types and the various types of foot orthoses, and athletic shoes are themselves often expensive. In addition, there are typically out-of-pocket costs associated with podiatry or orthotic services, or other vendors who provide orthoses.</p>
<p>The panel considered that the paucity of evidence for an important benefit due to any type of footwear or orthotic intervention in children and young people with JIA and, in particular, the lack of evidence for a difference between low-cost and high-cost interventions, implied that the more expensive interventions, particularly customised foot orthoses, would be least likely to be cost-effective, and that there was a high risk of families experiencing unnecessary healthcare costs.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Intervention likely increases inequity</span></div><div class="etd-domain-text"><p>There are a number of factors that may inï¬‚uence health opportunities and outcomes in individual patients. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may have an impact on equitable access to orthoses (particularly customised foot orthoses), podiatric care, and appropriate footwear.</p>
<p>The panel considered that the out-of-pocket costs associated with foot orthoses, particularly customised foot orthoses, and the need to access additional healthcare providers for the more customised interventions, would be likely to increase health inequity.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>It is plausible that there may be variation in acceptability of foot orthoses to stakeholders, including children and young people with JIA and their caregivers, based on their particular circumstances, including the extent and impact of the arthritis, the age of the patient, individual preferences, the effect on participation in social, sporting and vocational activities, and the impact on footwear choice.</p>
<p>While there is evidence that foot orthoses are generally positively perceived among users of lower extremity orthotic devices, there is relatively little evidence regarding acceptability to children and young people <sup><a href="https://doi.org/10.1016/j.apmr.2022.10.010" target="_blank" title="Orlando et al.">123</a></sup>.  In addition to concerns about shoe choice, acceptability may be influenced by factors that affect the accessibility of orthoses, including cost, durability, maintenance and rate of outgrowth <sup><a href="https://doi.org/10.1016/j.apmr.2022.10.010" target="_blank" title="Orlando et al.">123</a></sup>.</p>
<p>The panel considered that acceptability would be likely to vary depending on the type of footwear intervention, based on the wide differential in cost between highly customised foot orthoses, adapted and off-the-shelf prefabricated foot orthoses, and various types of footwear. Additionally, different types of interventions are associated with differences in convenience (including the number of visits to healthcare providers) and in impact on footwear choice, which is likely to lead to further variability in acceptability to consumers.</p>
<p>The panel also noted that acceptability often differs between young people with JIA and their parents, and that there is a risk that expensive orthoses may not be used by children or young people who find them uncomfortable or aesthetically unappealing.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Intervention is likely difficult to implement</span></div><div class="etd-domain-text"><p>The widespread use of foot orthoses in children and young people with JIA affecting the feet would require adequate and equitable access to appropriate devices, and to podiatrists and specialised services for custom-made orthoses.</p>
<p>The panel noted that while podiatrists often form part of the multidisciplinary team involved in the care of children and young people with JIA, the routine use of orthoses is not currently part of standard care, and that the costs associated with many orthotic devices would limit the feasibility of more widespread use.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-9-practical">
                    <div class="content-section">
                        <ul>
<li>All decisions regarding interventions in children and young people with juvenile idiopathic arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances.</li>
<li>Persistent foot pain in a child or young person with JIA suggests the need for assessment for treatable inflammation prior to consideration of orthotic interventions.</li>
<li>Asymptomatic, flexible, flat foot in children does not require treatment, and is a normal developmental finding in the first decade of life.</li>
<li>In children or young people with JIA who wish to trial an orthotic intervention, consider a relatively low-cost intervention (e.g. athletic shoes or other supportive footwear, or prefabricated foot orthoses). An ordered approach to intervention is advised, i.e. try shoes alone, then consider addition of prefabricated foot orthoses (which may be 'customised' in clinic) if foot symptoms persist.</li>
<li>A trial of different footwear with and without orthoses may be required, and the intervention need only be continued if the individual experiences improvement in symptoms with use and recurrence of symptoms without use of the particular combination of footwear and orthoses.</li>
<li>Expensive customised foot orthoses are unlikely to be necessary.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-9-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 8: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis, are foot orthoses safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1onFx5Zm7ib7Z3noBePUFdBZB-nNAjL3p/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-9-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Dr Samuel Whittle (Chair)</span>
<span class="panel-member">Prof Rachelle Buchbinder</span>
<span class="panel-member">Dr Angela Evans</span>
<span class="panel-member">Dr Jane Munro</span>
<span class="panel-member">Dr Renea Johnston</span>
<span class="panel-member">Chelsea Paech</span>
<span class="panel-member">David Pho</span>
<span class="panel-member">Dr Joachim Tan</span>
<span class="panel-member">Dr Georgina Tiller</span>
<span class="panel-member">Sarah Wilson</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">17 August 2023</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Foot%20orthoses%20for%20children%20and%20adolescents%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240278" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <div class="modal-overlay" id="modal-jia-rec-10">
        <div class="modal-content">
            <div class="modal-header">
                <div>
                    <div class="modal-category">Non-pharmacological interventions for JIA</div>
                    <h2 class="modal-title">Exercise therapy in children and young people with juvenile idiopathic arthritis</h2>
                </div>
                <button class="modal-close" onclick="closeModal()"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M6.28 5.22a.75.75 0 00-1.06 1.06L8.94 10l-3.72 3.72a.75.75 0 101.06 1.06L10 11.06l3.72 3.72a.75.75 0 101.06-1.06L11.06 10l3.72-3.72a.75.75 0 00-1.06-1.06L10 8.94 6.28 5.22z"/></svg></button>
            </div>
            <div class="modal-tabs-container"><div class="modal-tabs">
                <button type="button" class="modal-tab active" data-tab="recommendation" onclick="switchTab('jia-rec-10', 'recommendation')">Recommendation</button>
                <button type="button" class="modal-tab" data-tab="etd" onclick="switchTab('jia-rec-10', 'etd')">Evidence to Decision</button>
                <button type="button" class="modal-tab" data-tab="practical" onclick="switchTab('jia-rec-10', 'practical')">Practical Info</button>
                <button type="button" class="modal-tab" data-tab="data" onclick="switchTab('jia-rec-10', 'data')">Data</button>
                <button type="button" class="modal-tab" data-tab="moreinfo" onclick="switchTab('jia-rec-10', 'moreinfo')">More Info</button>
            </div></div>
            <div class="modal-body">
                <div class="tab-content active" id="jia-rec-10-recommendation">
                    <span class="strength-badge conditional-for">âŠ• Conditional Recommendation For</span>
                    <div class="recommendation-box"><p>In children and young people with JIA who have persistent symptoms or functional limitation despite optimal medical therapy, we conditionally recommend an exercise therapy programme that is tailored to their individual circumstances and needs.</p></div>
                    
                    <div class="content-section">
                        <h3>Rationale</h3>
                        <p>The panel reviewed evidence from randomised controlled trials (RCTs) of exercise therapy versus either a placebo intervention or no additional treatment. There was generally very low certainty evidence regarding the benefits and harms of exercise therapy, although there was low certainty evidence that exercise therapy may improve function and may slightly improve pain compared with no additional intervention.</p>
<p>The panel also considered evidence from trials that compared different types of exercise, however these trials also provided very low certainty evidence, and are difficult to interpret given the uncertainty in the primary comparison of exercise therapy versus placebo or no intervention.</p>
<p>There was very low certainty evidence regarding the risks associated with exercise therapy as trials were generally small and many did not collect or report adverse events. Adverse events were uncommon in the trials that reported data on harms, with the exception of a trial in which transient muscle soreness was common in those who undertook a strength training programme.</p>
<p>The trials primarily included children and adolescents with various types of JIA (mostly polyarticular or oligoarticular subtypes), most of whom were treated with disease-modifying pharmacotherapy including methotrexate, biological DMARDs, and glucocorticoids. Exercise therapy interventions varied between trials, however the majority were land-based and incorporated strength, aerobic and flexibility components, and were delivered over a 12 to 24 week period. The setting (home versus an exercise facility) and method of supervision also varied between trials.</p>
<p>The panel noted that while engagement in physical activity is generally considered to be a beneficial component of a healthy lifestyle and that adherence to general physical activity guidelines is a goal for all young people (including those with JIA) at the population level, this recommendation specifically refers to exercise therapy interventions at the individual level in children and young people with JIA.</p>
<p>Despite the relative paucity of evidence, the panel unanimously voted for a conditional recommendation in favour of exercise therapy. However, the panel noted that due to the advances in treatment of JIA over the last two decades, many children and young people with JIA are largely free from symptoms or any residual functional impairment and are therefore unlikely to require additional exercise interventions beyond advice and opportunities for physical activity afforded to the general population.</p>
<p>The panel discussed circumstances in which it considered the benefits of exercise therapy to be most likely, despite the lack of trial evidence regarding exercise therapy in specific populations of children and young people with JIA. It was considered that exercise therapy may be of particular value in individuals with persistent symptoms (particularly pain) or reduced function, as part of a multimodal approach to restoration of function and participation that is tailored to individual needs.</p>
<p>However the panel also noted that there may be considerable variation in specific needs and preferences across the range of ages of children and young people with JIA, and therefore any potential benefits and the associated trade-offs are likely to vary widely between individuals.</p>
<p>As a result, the panel favoured a conditional recommendation that recognises the importance of an individualised, shared decision-making approach that takes into account the particular circumstances, goals and preferences of each child or young person with JIA in their unique environment, and that in many cases no additional exercise therapy may be needed.</p>
<p>The consumer panellists reported that barriers to normal engagement in exercise and sports for children and young people with JIA may include uncertainty about which forms of exercise may help to restore function in the setting of arthritis, and concerns about the safety of certain forms of exercise in people with either active arthritis or musculoskeletal damage or deconditioning due to arthritis. In this situation, it was felt that design and supervision of a tailored exercise programme by a professional with expertise in this population would be likely to provide additional confidence and may improve engagement and outcomes.</p>
<p>It was also noted that a proportion of children and young people with JIA whose inflammation has been adequately treated or has resolved may continue to experience pain or other symptoms that may be a consequence of central sensitisation or other mechanisms. The panel formed the view that exercise therapy was also likely to be of benefit in this setting, as part of a multidisciplinary approach to chronic pain management, despite the lack of evidence regarding the benefits and harms of exercise therapy in this specific population of children and young people with JIA.</p>
<p>Given the current lack of evidence that any particular form of exercise therapy appears to be superior to other forms of exercise, the panel considered that it would be reasonable for children and young people with JIA who choose to undertake exercise therapy to select a form of therapy that suits their individual needs, goals, preferences, aptitude, and resources. While the current evidence provides very little certainty regarding the potential risks of exercise interventions, the likelihood of major harms appears to be low, however other trade-offs may also be important to consumers, including the cost of accessing exercise therapy, and the opportunity costs associated with time spent accessing and undertaking exercise therapy. For this reason, the consumer panellists expressed a preference for exercise interventions, where needed, that could be delivered in the home or near to home and with minimal equipment.</p>
<p>The panel emphasised the need for further high-quality research on this topic. This living recommendation will be updated if relevant new evidence emerges.</p>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-10-etd">
                    <div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Benefits and Harms</span><span class="etd-rating">Small net benefit, or little difference between alternatives</span></div><div class="etd-domain-text"><p><strong>Exercise therapy compared with attention-control placebo</strong></p>
<p><strong>Benefits</strong></p>
<ul>
<li>No studies were found that reported function, pain, quality of life, disease activity, global assessment of wellbeing, or fatigue.</li>
</ul>
<p><strong>Harms</strong></p>
<ul>
<li>Exercise therapy may have little or no effect on children and young people withdrawing from treatment for any reason.</li>
<li>We are uncertain if exercise therapy results in more children and young people reporting adverse events.</li>
</ul>
<p><strong>Exercise therapy compared with no additional treatment</strong></p>
<p><strong>Benefits</strong></p>
<ul>
<li>Exercise therapy may improve function and may improve pain slightly.</li>
<li>We are uncertain whether exercise therapy improves quality of life or disease activity.</li>
</ul>
<p><strong>Harms</strong></p>
<ul>
<li>Exercise therapy may have little or no effect on children and young people withdrawing from treatment for any reason.</li>
</ul></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Certainty of the Evidence</span><span class="etd-rating">Very low</span></div><div class="etd-domain-text"><p><em>Primary comparisons (Exercise therapy compared with placebo ('attention-control'); Exercise therapy compared with no additional treatment):</em></p>
<p>The certainty of evidence was low to very low for all outcomes.</p>
<p>For the placebo comparison, evidence for withdrawals due to any reason was downgraded to low-certainty due to the potential for performance and detection bias from unblinded participants, and imprecision due to the small number of events; while evidence for adverse events was downgraded to very low-certainty for bias and twice for imprecision due to a very small number of events. No other outcomes were reported for this comparison.</p>
<p>For the no additional treatment comparison, evidence was low-certainty for function and pain and withdrawal from treatment for any reason, due to the potential for selection, performance and detection bias from unblinded participants, and imprecision. Evidence was downgraded once more to very low-certainty for quality of life and disease activity, due to some indirectness of the interventions.</p>
<p><em>Secondary comparison (Exercise therapy compared with a different exercise therapy):</em></p>
<p>Evidence for trials comparing one type of exercise to another was very low-certainty for all outcomes except function due to potential for bias, imprecision and indirectness (some of the exercise therapies are customised and trial specific). Evidence for function was not imprecise, and considered low-certainty.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Values and Preferences</span><span class="etd-rating">Substantial variability is expected or uncertain</span></div><div class="etd-domain-text"><p>There are few data regarding the preferences of children and young people with JIA and their families regarding non-pharmacological interventions. In general, outcomes of importance to children and young people with JIA include reduction in pain, reduced frequency of disease flares, improved quality of life, and the ability to engage in normal social, educational and sporting activities <sup><a href="https://doi.org/10.1186/s12969-023-00906-8" target="_blank" title="McErlane et al.">144</a></sup><sup><a href="https://doi.org/10.3899/jrheum.131536" target="_blank" title="Guzman et al.">145</a></sup><sup><a href="https://doi.org/10.11124/JBIES-21-00139" target="_blank" title="Min et al.">146</a></sup>. Potential adverse consequences of exercise therapies, including pain, and the associated time burden or other opportunity costs, have been identified as barriers to engagement in exercise programmes among children and young people with JIA <sup><a href="https://doi.org/10.1177/030802260907200806" target="_blank" title="De et al.">143</a></sup>. There are likely to be differences between individuals in their weighting of these trade-offs.</p>
<p>Two rounds of voting were undertaken for this domain. In the first round, the majority of panellists considered that â€œsubstantial variability is expected or uncertainâ€, however a third of panellists considered that â€œno substantial variability is expectedâ€. These panellists were of the view that nearly all families would consider exercise to be an important component of a healthy life and that any variability may focus on the best method of enhancing access and engagement with exercise for children and young people with JIA. Although a unanimous consensus was not reached, a second round of voting indicated that the majority of panellists still considered that there was likely to be variability between individuals.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Resources</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>We did not identify any cost-effectiveness data regarding exercise therapy in children and young people with JIA. Exercise therapies may entail an out-of-pocket cost for families that is likely to vary considerably according to the type of exercise and the context in which it is performed. Similarly, the impact of this cost is likely to vary between individuals, but may represent an important barrier to access in many cases, particularly in light of the current relatively high cost-of-living in Australia.</p>
<p>Out-of-pocket costs may be mitigated in some instances by community or government services, including subsidised access to allied health professionals (including exercise physiologists and physiotherapists) via a Chronic Disease Management plan. However such subsidies are limited in their extent and may not offset the full cost of an exercise intervention.</p>
<p>There is unlikely to be a major impact of exercise interventions on the environment.</p>
<p>While most panellists considered that resource issues may be important to this recommendation, some panellists voted in favour of â€œno important issuesâ€ and the consensus view was that while resources are likely to be a consideration, this was unlikely to be the major factor in this recommendation.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Equity</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There are a number of factors that may inï¬‚uence health opportunities and outcomes in individual patients. Such factors (based on the PROGRESS-Plus characteristics) might include poor health literacy; residence in rural, remote or relatively under-serviced locations; primary language other than English; low educational attainment; the presence of disability; or adverse socioeconomic or social circumstances. Some of these may have an impact on equitable access to exercise interventions or may present additional barriers to a sustained exercise practice.</p>
<p>The panel considered that while there may be potential for a recommendation in favour of exercise therapy to increase health inequity, the impact would be likely to vary depending on the form of therapy and the methods by which exercise therapies are delivered and funded.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Acceptability</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>There is likely to be variation in acceptability of exercise interventions to stakeholders, including children and young people with JIA and their caregivers, based on their particular circumstances, including the extent and impact of the arthritis, the age of the patient, costs, accessibility of equipment or services, and individual preferences.</p>
<p>The initial round of voting in this domain was evenly divided between panellists who considered there to be â€œimportant issues, or potential issues not investigatedâ€ and those who considered there to be â€œno important issuesâ€. On further discussion, the panel considered that exercise is likely to be broadly acceptable at the population level, but that there was likely to be variability in the acceptability and implementation of specific exercise therapies at the individual level.</p></div></div>
<div class="etd-domain"><div class="etd-domain-header"><span class="etd-domain-title">Feasibility</span><span class="etd-rating">Important issues, or potential issues not investigated</span></div><div class="etd-domain-text"><p>The widespread introduction of exercise interventions for children and young people with JIA would require adequate and equitable access to facilities, equipment and allied health professionals.</p>
<p>Some panellists considered that exercise interventions would be difficult to implement. They noted the particular challenges of creating interventions that can be implemented in a standardised fashion but which still meet the needs of individuals. The panel formed the view that these issues are likely to require further investigation.</p></div></div>
                </div>
                <div class="tab-content" id="jia-rec-10-practical">
                    <div class="content-section">
                        <ul>
<li>All decisions regarding interventions in children and young people with juvenile idiopathic arthritis should be made within a shared decision-making framework following a clear discussion of potential benefits and harms, tailored to the individual's circumstances.</li>
<li>All children and young people, including those with JIA, are encouraged to participate in physical activity at recommended levels.
    <ul>
    <li><a href="https://www.health.gov.au/topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians/for-children-and-young-people-5-to-17-years" target="_blank">Australian Physical Activity and Sedentary Behaviour Guidelines</a> recommend at least 60 minutes a day of moderate to vigorous physical activity in children and young people aged 5 to 17 years.</li>
    </ul>
</li>
<li>A tailored exercise therapy intervention may be of most value in children and young people with JIA who continue to experience pain, loss of function, or reduced participation in sport or social activities, despite adequate control of their arthritis.</li>
<li>Individual goals of therapy should be co-developed, but would generally be expected to focus on restoration of function or improvement in participation.</li>
<li>Adherence to an exercise programme may be enhanced if the exercise therapy is accessible, affordable, enjoyable, and developed in conjunction with a trusted healthcare professional.</li>
</ul>
                    </div>
                </div>
                <div class="tab-content" id="jia-rec-10-data"><div class="data-content">
                    <div class="pico-box">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a.75.75 0 000 1.5h.253a.25.25 0 01.244.304l-.459 2.066A1.75 1.75 0 0010.747 15H11a.75.75 0 000-1.5h-.253a.25.25 0 01-.244-.304l.459-2.066A1.75 1.75 0 009.253 9H9z" clip-rule="evenodd"/></svg>PICO 9: Clinical Question (PICO)</h3>
                        <p class="pico-text">In children and young people with juvenile idiopathic arthritis with persistent symptoms or functional limitation, is exercise therapy safe and effective?</p>
                    </div>
                    <div class="evidence-section">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width:18px;height:18px;vertical-align:text-bottom;margin-right:6px;"><path d="M10.75 16.82A7.462 7.462 0 0115 15.5c.71 0 1.396.098 2.046.282A.75.75 0 0018 15.06v-11a.75.75 0 00-.546-.721A9.006 9.006 0 0015 3a8.963 8.963 0 00-4.25 1.065V16.82zM9.25 4.065A8.963 8.963 0 005 3c-.85 0-1.673.118-2.454.339A.75.75 0 002 4.06v11a.75.75 0 00.954.721A7.462 7.462 0 015 15.5c1.579 0 3.042.487 4.25 1.32V4.065z"/></svg>Evidence Summaries</h3>
                        <ul class="evidence-list">
                            <li><a href="https://drive.google.com/file/d/1ljt7yF_tcBopYXYzHvJ8hdxBfSVSnWu2/view?usp=share_link" target="_blank">Evidence Synthesis (October 2025)</a></li>
                        </ul>
                    </div>
                </div></div>
                <div class="tab-content" id="jia-rec-10-moreinfo">
                    <div class="panel-info">
                        <h3><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path d="M10 8a3 3 0 100-6 3 3 0 000 6zM3.465 14.493a1.23 1.23 0 00.41 1.412A9.957 9.957 0 0010 18c2.31 0 4.438-.784 6.131-2.1.43-.333.604-.903.408-1.41a7.002 7.002 0 00-13.074.003z"/></svg> Panel Members</h3>
                        <div class="panel-members"><span class="panel-member chair">Dr Samuel Whittle (Chair)</span>
<span class="panel-member">Prof Rachelle Buchbinder</span>
<span class="panel-member">Dr Priscilla Campbell-Stokes</span>
<span class="panel-member">Cass Gannon</span>
<span class="panel-member">Rebecca Hazel</span>
<span class="panel-member">Dr Jane Munro</span>
<span class="panel-member">Ishani Perera</span>
<span class="panel-member">David Pho</span>
<span class="panel-member">Dr William Renton</span>
<span class="panel-member">Prof Lyndal Trevena</span></div>
                    </div>
                    <div class="info-item">
                        <div class="info-icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M5.75 2a.75.75 0 01.75.75V4h7V2.75a.75.75 0 011.5 0V4h.25A2.75 2.75 0 0118 6.75v8.5A2.75 2.75 0 0115.25 18H4.75A2.75 2.75 0 012 15.25v-8.5A2.75 2.75 0 014.75 4H5V2.75A.75.75 0 015.75 2zm-1 5.5c-.69 0-1.25.56-1.25 1.25v6.5c0 .69.56 1.25 1.25 1.25h10.5c.69 0 1.25-.56 1.25-1.25v-6.5c0-.69-.56-1.25-1.25-1.25H4.75z" clip-rule="evenodd"/></svg></div>
                        <div class="info-content">
                            <div class="info-label">Panel Meeting Date</div>
                            <div class="info-value">30 May 2024</div>
                        </div>
                    </div>
                </div>
            </div>
            <div class="modal-footer">
                <div class="modal-footer-left">
                    <span class="card-updated">Last updated: October 2025</span>
                    <a href="https://docs.google.com/forms/d/e/1FAIpQLSfarxWPaubepAaUzvm3HLxMgM57JlzKRtej-eWcRt7vw4wBAg/viewform?usp=pp_url&entry.1797546299=Therapeutic%20exercise%20for%20children%20with%20JIA" target="_blank" class="feedback-link">
                        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor" style="width: 16px; height: 16px;">
                            <path d="M3 4a2 2 0 00-2 2v1.161l8.441 4.221a1.25 1.25 0 001.118 0L19 7.162V6a2 2 0 00-2-2H3z"/>
                            <path d="M19 8.839l-7.77 3.885a2.75 2.75 0 01-2.46 0L1 8.839V14a2 2 0 002 2h14a2 2 0 002-2V8.839z"/>
                        </svg>
                        Suggest feedback
                    </a>
                </div>
                <div class="modal-footer-right">
                    <a href="https://app.magicapp.org/#/guideline/10522/section/240279" target="_blank" class="magicapp-link">View in MAGICapp <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor"><path fill-rule="evenodd" d="M4.25 5.5a.75.75 0 00-.75.75v8.5c0 .414.336.75.75.75h8.5a.75.75 0 00.75-.75v-4a.75.75 0 011.5 0v4A2.25 2.25 0 0112.75 17h-8.5A2.25 2.25 0 012 14.75v-8.5A2.25 2.25 0 014.25 4h5a.75.75 0 010 1.5h-5z" clip-rule="evenodd"/><path fill-rule="evenodd" d="M6.194 12.753a.75.75 0 001.06.053L16.5 4.44v2.81a.75.75 0 001.5 0v-4.5a.75.75 0 00-.75-.75h-4.5a.75.75 0 000 1.5h2.553l-9.056 8.194a.75.75 0 00-.053 1.06z" clip-rule="evenodd"/></svg></a>
                </div>
            </div>
        </div>
    </div>

    <footer>
        <div class="footer-container">
            <div class="footer-grid">
                <div class="footer-brand">
                    <h3>Australian Living Guidelines</h3>
                    <p>Evidence-based clinical recommendations for the management of inflammatory arthritis, developed through collaboration between leading Australian rheumatology organisations.</p>
                </div>
                <div class="footer-column">
                    <h4>Guidelines</h4>
                    <a href="../adult/">Adult Inflammatory Arthritis</a>
                    <a href="../jia/">Juvenile Idiopathic Arthritis</a>
                </div>
                <div class="footer-column">
                    <h4>About</h4>
                    <a href="../who-we-are.html">Who We Are</a>
                    <a href="../methodology.html">Methodology</a>
                    <a href="../funding.html">Funding & Support</a>
                    <a href="../publications.html">Publications</a>
                </div>
                <div class="footer-column">
                    <h4>Resources</h4>
                    <a href="../abbreviations.html">Abbreviations</a>
                    <a href="../contact.html">Contact Us</a>
                </div>
            </div>
            <div class="footer-bottom">
                <div class="footer-copyright">&copy; 2025 ANZMUSC Clinical Trials Network. All rights reserved.</div>
            </div>
        </div>
    </footer>

    <script>
        let activeTag = null;
        let searchQuery = '';

        function filterCards() {
            let visibleCount = 0;
            document.querySelectorAll('.recommendation-card').forEach(card => {
                const tags = card.dataset.tags || '';
                const title = card.querySelector('.card-title')?.textContent.toLowerCase() || '';
                const recommendation = card.querySelector('.card-recommendation')?.textContent.toLowerCase() || '';
                const category = card.querySelector('.card-category')?.textContent.toLowerCase() || '';
                
                const onclickAttr = card.getAttribute('onclick') || '';
                const modalIdMatch = onclickAttr.match(/openModal\('([^']+)'\)/);
                let modalContent = '';
                
                if (modalIdMatch && searchQuery) {
                    const modalId = modalIdMatch[1];
                    const modal = document.getElementById('modal-' + modalId);
                    if (modal) modalContent = modal.textContent.toLowerCase();
                }
                
                const matchesTag = !activeTag || tags.includes(activeTag);
                const matchesSearch = !searchQuery || 
                    title.includes(searchQuery) || 
                    recommendation.includes(searchQuery) || 
                    category.includes(searchQuery) ||
                    tags.includes(searchQuery) ||
                    modalContent.includes(searchQuery);
                
                const isVisible = matchesTag && matchesSearch;
                card.classList.toggle('hidden', !isVisible);
                if (isVisible) visibleCount++;
            });
            
            document.getElementById('no-results').style.display = visibleCount === 0 ? 'block' : 'none';
        }

        const searchInput = document.getElementById('search-input');
        const searchClear = document.getElementById('search-clear');

        searchInput.addEventListener('input', function() {
            searchQuery = this.value.toLowerCase().trim();
            searchClear.classList.toggle('visible', searchQuery.length > 0);
            filterCards();
        });

        function clearSearch() {
            searchInput.value = '';
            searchQuery = '';
            searchClear.classList.remove('visible');
            filterCards();
        }

        document.querySelectorAll('.tag-filter').forEach(btn => {
            btn.addEventListener('click', function() {
                if (this.classList.contains('active')) {
                    this.classList.remove('active');
                    activeTag = null;
                } else {
                    document.querySelectorAll('.tag-filter').forEach(b => b.classList.remove('active'));
                    this.classList.add('active');
                    activeTag = this.dataset.tag;
                }
                filterCards();
            });
        });

        function openModal(modalId) {
            document.querySelectorAll('.modal-overlay').forEach(modal => modal.classList.remove('active'));
            const modal = document.getElementById('modal-' + modalId);
            if (modal) { 
                modal.classList.add('active'); 
                document.body.style.overflow = 'hidden';
                const modalBody = modal.querySelector('.modal-body');
                if (modalBody) modalBody.scrollTop = 0;
                switchTab(modalId, 'recommendation');
            }
        }

        function closeModal() {
            document.querySelectorAll('.modal-overlay').forEach(modal => modal.classList.remove('active'));
            document.body.style.overflow = '';
        }

        function switchTab(modalId, tabId) {
            const modal = document.getElementById('modal-' + modalId);
            if (!modal) return;
            modal.querySelectorAll('.modal-tab').forEach(tab => tab.classList.toggle('active', tab.dataset.tab === tabId));
            modal.querySelectorAll('.tab-content').forEach(content => content.classList.remove('active'));
            const tabContent = document.getElementById(modalId + '-' + tabId);
            if (tabContent) tabContent.classList.add('active');
        }

        document.querySelectorAll('.modal-overlay').forEach(modal => {
            modal.addEventListener('click', function(e) { if (e.target === this) closeModal(); });
        });

        document.addEventListener('keydown', function(e) { if (e.key === 'Escape') closeModal(); });

        function checkHashAndOpenModal() {
            const hash = window.location.hash;
            if (hash && hash.startsWith('#jia-rec-')) {
                const modalId = hash.substring(1);
                openModal(modalId);
            }
        }

        document.addEventListener('DOMContentLoaded', checkHashAndOpenModal);
        window.addEventListener('hashchange', checkHashAndOpenModal);
    </script>
</body>
</html>
